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The five year survivorship rate of females diagnosed with breast cancer is 88% across 
Canada (Canadian Cancer Society, 2015). Often, treatments can cause damage to the tissue 
which may lead to impairment of upper limb function, specifically range of motion and strength. 
There have been several attempts to quantify these changes, but to inconclusive extents. This 
study investigated differences between breast cancer survivors with low and high self-reported 
physical functioning scores, differences between affected and unaffected limbs, as well as 
differences after 4 months of usual care. Ten female breast cancer survivors (between 3 months 
and 2 years post treatment) completed six maximal strength trials (flexion, extension, abduction, 
adduction, internal and external rotation) per limb and six maximal range of motion trials 
(flexion, extension, abduction, scapular plane abduction, and internal and external rotation), 
along with three questionnaires. Groups were split based on scores from the disability of arm, 
shoulder and hand (DASH) questionnaire. Maximal strength was compared for strength trials, 
and glenohumeral elevation was compared for range of motion trials. For both sets of trials, 
peak, median and static muscular activity was compared for high and low physical function 
scores as well as between affected and unaffected limbs. No differences were found between 
affected and unaffected limbs for either strength or range of motion. However, flexion, 
extension, abduction, and adduction strength were 32-52% higher in the group with higher self-
reported physical functioning scores compared to the group with lower self-reported physical 
function scores. Correspondingly, internal rotation range of motion was 1.92 times higher in the 
group with higher physical function scores (effect size =1.98). The other five range of motion 
tasks (abduction, flexion, extension, scapular plane abduction and external rotation) were not 
statistically different between groups of high and low physical function scores but had moderate 
to large effect sizes (0.42-0.94). Several measures were correlated with DASH scores, indicating 
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that increased strength and range of motion relate to self-reported physical functioning in breast 
cancer survivors. Between baseline and follow up, none of the six measured strengths changed, 
with only one of the six range of motion measures increased over the four month period. 
Extension range of motion increased by 112% during this period of usual care. Overall, this 
thesis provides insight into the period of time immediately following treatment. These variables 
had not been evaluated within the first two years of survivorship. Additionally, this work 
suggests breast cancer survivors are not a homogenous group, and that function (range of motion 
and strength) differ. In previous literature, all outcomes are reported from one group and have 
been inconclusive. However this work shows that there may be a difference in survivors’ 
function. This can help refine future rehabilitation strategies as the deficits for these individuals 
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In Canada, 1 in 9 women will be diagnosed with breast cancer in their lifetime, which can 
have lasting effects beyond the end of treatment into survivorship. With advances in oncological 
treatment and raised awareness leading to early detection, the 5-year survival rate is currently 
88% (Canadian Cancer Society, 2015). Many of these survivors, however, live with residual 
impairment following primary cancer treatment. Along with physical limitations, approximately 
6-70% of breast cancer survivors live with lymphedema (Ahmed et al., 2006; Rietman et al., 
2003), 31-61% with pain (Lauridsen et al., 2008), 60-96% with fatigue during treatment, and up 
to 25% with lasting fatigue (Stasi et al., 2003). These can exist among other co-morbidities that 
ultimately lead to a decreased quality of life in many survivors. Decreased arm function 
associates with a decreased quality of life of in breast cancer survivors (Rietman et al., 2003; 
Yang et al., 2010). Beyond arm functional ability, treatment type, age at diagnosis and body 
image all affect quality of life scores (Arndt et al., 2008; Howard-Anderson et al., 2012).  
Exercise and other therapies are suggested to help mitigate the impairment in the breast 
cancer survivor population. With many confounding factors across these therapies, it is difficult 
to determine the effectiveness of each therapy. Exercise is known to increase quality of life 
(Courneya et al., 2014), and range of motion (McNeely et al., 2010) of breast cancer survivors. 
However, debate remains around the time to begin exercise, especially as it pertains to secondary 
symptoms such as lymphedema. Therapies such as acupuncture and massage have further been 
suggested to help decrease these secondary symptoms (Kang et al., 2014; Yao et al., 2016).  
Strength, muscular activation patterns, glenohumeral range of motion and scapular 
kinematics are influenced by the occurrence of breast cancer. A 10% reduction in grip strength in 
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the affected limb, compared to the unaffected limb is present in 20-43% of patients (Bendz and 
Fagevik Olsén, 2002; Kuehn et al., 2000). Additionally, a loss in force production is exhibited in 
extensors, protractors and retractors of the shoulder on the affected limb (Merchant et al., 2008). 
The musculature surrounding the glenohumeral joint maintains the stability of the joint, however 
the strategy to reach this is altered in breast cancer survivors due to specific muscular 
deficiencies (Brookham and Dickerson, 2015; Chopp-Hurley et al., 2016; Shamley et al., 2007). 
Range of motion is affected for up to 77% of breast cancer survivors. Decreased range of motion 
in flexion, abduction and external rotation may be present, particularly in patients who received 
mastectomies and radiation therapy (Harrington et al., 2013; Lauridsen et al., 2008). Finally, 
increases in scapular internal rotation and upward rotation have been noted in the affected arm 
(Borstad and Szucs, 2012; Crosbie et al., 2010), which could increase the likelihood of 
subacromial impingement syndrome (Ludewig and Reynolds, 2009). Decreased strength and 
range of motion, and alterations in kinematic strategies and activation patterns affect breast 
cancer survivor’s ability to complete daily activities. However, no existing work has quantified 
arm and shoulder function over time to account for natural healing processes and establish early 
recovery characteristics. By quantifying the abilities and function of the affected arm, more 
targeted exercise programs can be created, and their effectiveness can be evaluated.  
1.1 Objective 
The purpose of this research is to quantify the upper limb function in a group of acute 
breast cancer survivors (three months to two years post treatment). Specifically, this entails 
delineating differences in strength and glenohumeral range of motion in high functioning and 
low functioning breast cancer survivors (as determined by various questionnaires), as well as 
comparison of these variables in the affected and unaffected limb in a group of survivors.  
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1.2 Research Questions 
The primary research questions are: 
1. Do breast cancer survivors with lower self-reported function scores have decreased 
strength and range of motion compared to a group with high self-reported function 
scores? 
2. Does a relationship exist between shoulder strength and/or range of motion and self-
reported physical function scores?  
3. Does the affected limb of breast cancer survivors have decreased strength and range of 
motion compared to the unaffected limb? 
4. Is traditional care coincident with altered strength and range of motion over a 4 month 
period? 
1.3 Hypotheses 
It is hypothesized that: 
1. Participants with higher physical functioning will have increased strength. 
2. Participants with higher physical functioning will have increased range of motion. 
3. Participants with higher physical functioning will be more physically active than those 
with lower physical functioning. 
4. There will be no quantifiable differences between baseline and follow up sessions, 
following four months of usual care.  
1.4 Significance of Research  
 This investigation quantified the physical capabilities, such as range of motion and 
strength, of the shoulder in breast cancer survivors. Additionally, longitudinal changes were 
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investigated in a subset of participants, providing initial insight into post treatment changes in 
arm function. With the population of breast cancer survivors increasing consistently, it is 
imperative to produce full descriptions of the physical capabilities of breast cancer survivors 
immediately following treatment. Quantification of the consequences of primary breast cancer 
treatment on the shoulder can lead to more targeted rehabilitation programs, while also providing 
insight into breast cancer survivors’ arm function with respect to early healing. This thesis works 
to identify differences in survivors with high self-reported physical function with those with low 
self-reported physical function scores. By identifying the differences in strength, range of 
motion, and demographics within these two groups, it may provide insight into why there is 
variability in survivors’ function and identify the deficit in the survivors with lower physical 
function Considering the lack of rigorously collected quantitative data in this population, this 
thesis work strengthens overall awareness of survivor capabilities and can help to identify return 
to work strategies. 
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2.0 Literature Review 
2.1 Breast Cancer Overview 
2.1.1 Prevalence 
Breast cancer is the most common cancer diagnosis in Canadian females.  In Canada, 1 in 9 
females will be diagnosed with breast cancer in their lifetime and accounts for 25.9% of new 
cancer cases each year. Of those diagnosed, 52% are between the ages of 50 and 69 years.  
However, 5-year survivorship has reached 87-90% in women between the ages of 40 and 79 
years (Canadian Cancer Society, 2015).  
Several factors may increase the likelihood of developing breast cancer. Hormonal factors 
such as breastfeeding, menopause, older age at pregnancy, and oral contraceptives may increase 
the risk of diagnosis. A stabilization in new cases occurred (around 2004) when hormone 
replacement therapy was no longer used among postmenopausal women (Canadian Cancer 
Society, 2015).  Further, a combination of genetic and environmental factors most likely leads to 
the development of breast cancer. Additionally, a family history of the disease is associated with 
the likelihood of developing breast cancer, increasing the risk by 2-4 times (Fisher et al., 1986).  
2.1.2 Stages of Breast Cancer 
The stages of breast cancer (Table 1) are defined by four characteristics: size, invasive or 
non-invasive, whether cancer is in the lymph nodes, and if the cancer has spread beyond the 
breast tissue (metastasized). The stages increase in severity ranging from stage 1A where there is 
an invasive tumour up to 2cm in diameter, to Stage IV where cancer has spread beyond the 





Table 1: Stages of breast cancer progression (Edge et al., 2010) 
Stage Description 
Stage IA  Non-invasive or Invasive 
 Tumour is up to 2cm 
 Contained to breast tissue 
Stage IB  Invasive 
 Less than 2mm group of cells in lymph nodes 
 Less than 2cm tumour in breast tissue 
Stage IIA  1 to 3 axillary lymph nodes  
 Tumour measures 2cm or smaller OR 
 Tumour between 2-5cm but has not spread to lymph nodes 
Stage IIB  Tumour is between 2-5cm and spread to 1 to 3 axillary lymph nodes 
OR 
 Tumour is larger than 5cm but not spread 
Stage IIIA  Tumour is in 4 to 9 axillary lymph nodes  
 Larger than 5cm 
Stage IIIB  Any size tumour and spread to chest wall causing swelling 
 Spread to up to 9 axillary lymph nodes 
Stage IIIC  Tumour of any size 
 Spread to 10 or more axillary nodes OR 
 Spread to lymph nodes above or below the clavicle 
Stage IV  Spread beyond lymph nodes and breast tissue 
 
2.1.3 Surgical Treatments 
 Surgical treatments are commonly used as an initial intervention for breast cancer, 
followed by an adjuvant therapy to ensure that the entire tumour has been removed, and no 
cancerous cells remain. Mastectomy is still the most common surgical treatment (45% of total 
surgical procedures), followed by breast conserving treatment (5% of the total, only where 
advanced technology exists) and finally axillary node dissection in more advanced tumours 




 Both radical and modified radical mastectomies are both commonly used surgical 
strategies for breast cancer treatment. Mastectomies are the most effective surgical treatment 
with only 4.4% of patients suffering a relapse (Van Der Sangen et al., 2011). Radical 
mastectomies involve removing the breast tissue, overlying skin, pectoralis muscle and extensive 
lymph node dissection (Dalberg et al., 2010). With the complete removal of the muscle and 
tissue, this surgery (along with any adjuvant treatments) is associated with extensive range of 
motion and lymphedema iatrogenic complications (up to 79% of patients present with one or 
both) (Sugden et al., 1998).  With increases in imaging accuracy and the effectiveness of 
adjuvant therapies, modified radical mastectomy procedures have increased in popularity. In this 
treatment, the pectoral fascia is removed, but the muscle itself remains intact. Removing the 
fascia increases difficulty in reconstruction following treatment (compared to sparing the 
pectoral fascia), but decreases cancer reoccurrence at the chest-wall (Dalberg et al., 2010). The 
modified radical mastectomy significantly reduces the incidence of lymphedema, and improves 
the range of motion restrictions apparent in this population (Dalberg et al., 2010; Sugden et al., 
1998).  Even when radiation therapy is added following surgery, range of motion remains 
compromised as scar tissue forms between layers of muscle, causing adhesions. Of  patients that 
received modified radical mastectomy and radiation therapy, 35% had range of motion 
restrictions in one or more directions (Lauridsen et al., 2008). 
2.1.3.2 Breast Conserving Therapy (Wide Local Excision/Lumpectomy)  
 Breast conserving therapy is a less severe surgical treatment used in breast cancer 
diagnoses. In western countries, breast conserving treatment is the currently preferred method of 
treatment. Although used 4% world-wide, breast conserving treatment is used ~30% in 
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developed countries (Nemoto et al., 1980; Van Der Sangen et al., 2011). However, large 
tumours, and tumours that have spread, require mastectomies. Additionally, mastectomies 
remain dominant due to their preference in less developed countries, (Dalberg et al., 2010). 
Breast conserving treatments are more readily available in western countries, as they are 
dependent on early diagnosis (Markes et al., 2006) and are highly effective with a 6% relapse 
rate (Van Der Sangen et al., 2011). This treatment involves removing only the cancerous tissues, 
with a margin of 3mm (Rietman et al., 2003) without removal of lymph nodes, reducing 
occurrences of lymphedema (Nesvold et al., 2008). However, differences in limb function 
between breast conserving therapy and modified radial mastectomies are unclear. Several studies 
detected no differences between upper limb function after each surgery (without radiation 
therapy following) (Kuehn et al., 2000; Lauridsen et al., 2008), while others reported that 
patients receiving breast conserving therapy had less impairment than those receiving modified 
radical mastectomies (Nesvold et al., 2008; Sugden et al., 1998). The decrease in impairment is 
likely impacted by differences in follow up time and quantification of impairment. Impairment 
was defined as a reduction in range of motion greater than 25
°
 (Nesvold et al., 2008), or greater 
than 10
°
  (Kuehn et al., 2000). The differences in classifications of impairments may lead to the 
inconclusive findings.  
2.1.3.3 Axillary Lymph Node Dissection 
 Axillary lymph node dissection is used when the cancer has spread beyond the breast 
tissue into the lymphatic system. It is suggested that if the tumour is larger than 5mm, the 
lymphatic nodes in the axilla will test positive for cancerous tissue and therefore it is beneficial 
to have this surgery (Hack et al., 1999). This surgery is more invasive than the aforementioned 
techniques, and therefore pain, numbness, lymphedema and dysfunction are all more likely to 
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occur with this approach. Although these symptoms decrease in severity, for many women they 
persist. Six months post surgery, 61% of survivors  reported numbness, but only 17% reported 
pain, while functional deficits (range of motion and strength decreases) existed in 31% of 
patients (Hack et al., 1999).  
 Many complications may arise from axillary lymph node dissection. Compared to other 
less invasive surgical treatments, breast cancer survivors who had axillary lymph node dissection 
experienced more pain and greater restrictions in range of motion. As well, occurrence of 
lymphedema increased when this surgery was performed in combination with radiation. Range 
of motion was also compromised, and related to the number of lymph nodes that were dissected 
(Hack et al., 2010). Specifically, at 2 years post surgery, there was a statistically significant 
decrease in abduction and flexion range of motion in patients who received axillary lymph node 
dissection. This decrease was more prominent in patients who immobilized the arm for 2 weeks 
following surgery prior to commencing exercise (Bendz and Fagevik Olsén, 2002).  
2.1.4 Radiation Therapy  
 Radiation therapy is a localized adjuvant therapy used after surgical intervention with 
several known side effects. The localization of radiation therapy can help control cancer within a 
region. Radiation damages the DNA of cells directly (or through the release of free radicals). 
However, radiation frequently damages other local cells (Courneya et al., 2002), causing fatigue 
and skin erythema, lymphedema, cardiac and pulmonary toxicities and brachial plexopathy 
(Truong et al., 2004). When combining surgical interventions with radiation in breast cancer 
treatment, scar tissue often forms between the musculature at the glenohumeral joint, limiting the 
range of motion due to adhesions (Lauridsen et al., 2008; Markes et al., 2006). Although it is the 
most common adjuvant therapy due to its ability to localize treatment, radiation increases range 
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of motion deficits, while also increasing the likelihood of developing lymphedema (Hack et al., 
1999). As the lymphatic system is present in the axilla, radiation damages the nodes, and affects 
the drainage of the limb. When the damage is too intense, lymphedema occurs (Truong et al., 
2004).  
2.1.5 Chemotherapy Treatment 
 Chemotherapy is a common cancer treatment chosen to manage suspected 
rnicrometastases (cancerous cells that have spread, but are too small to detect). Generally, 9-21 
weeks of this treatment are completed in 4-8 cycles, most often intravenously but can also be 
taken orally (Courneya et al., 2002). Unlike radiation and surgical procedures, chemotherapy is 
not localized. The drugs utilized in chemotherapy affect many tissues in the body, as it can be 
difficult to only attack cancerous cells, causing many additional side-effects.  
 Chemotherapy is implicated as a cause for fatigue, nausea, weight gain and an overall 
decrease in patient quality of life (Markes et al., 2006). Chemotherapy recipients reported 
generally decreased arm function, and were less likely to participate in exercise compared to 
those who did not receive chemotherapy (Markes et al., 2006; Tiezzi et al., 2016). Combined 
with fatigue and weight gain, the lack of exercise perpetuates physical dysfunction, and quality 
of life remains poor. Additionally, patients demonstrate lack of motivation to exercise during or 
after chemotherapy treatments, unless the apparent benefits are clear or the program is perceived 
as enjoyable (Courneya et al., 2016).  
2.1.6 Hormonal Treatment  
Hormonal therapy is a treatment prescribed if the tumour is considered estrogen receptor 
positive. This indicates that estrogen promotes tumor growth.  The hormone therapy stops or 
slows down the production of estrogen production and is often taken orally, everyday and can be 
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continued for many years. The therapy may cause fatigue and weight gain (Courneya et al., 
2002). In some scenarios, the ovaries are removed to halt estrogen production. For both surgical 
hormonal treatment and oral medication, the production of estrogen is slowed or ceased to 
prevent the continuous growth of the tumour (Canadian Cancer Society, 2015). This treatment 
promotes early menopause, and affects bone resorption, leading to increased bone loss and 
ultimately an increased likelihood of fractures (Courneya et al., 2002; Poznak, 2015). This 
treatment does not appear to explicitly affect shoulder musculature or function. 
2.2 Survivorship 
2.2.1 Quality of Life following Breast Cancer Diagnosis and Treatment 
 Quality of life provides insight into perceived abilities of survivors, and how these differ 
with various treatments. With a large breast cancer survivor population, it is increasingly 
important to identify address issues associated with quality of life. Women undergoing breast 
conserving therapy tend to have higher quality of life ratings than those who have a mastectomy. 
They report better physical function, social function, and continue to pursue work and leisure 
activities. Comparatively, women who have a mastectomy report poor scores for almost all 
physical function scales (Arndt et al., 2008).  The differences in these two surgical methods are 
likely determinants of the divergent post-operative quality of life measures. The less invasive 
breast conserving therapy, complemented by breast reconstruction enhances quality of life by 
increasing body image and self-confidence in breast cancer survivors (Arndt et al., 2008). 
Further, decreases in quality of life are correlated with decreased function of the upper extremity 
more than body image (Kuehn et al., 2000; Rietman et al., 2003; Yang et al., 2010).  
 Beyond physical function, quality of life can be influenced by changes in psychological 
health. Depression, anxiety and increased stress are prevalent in breast cancer survivors. 
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Particularly, younger women diagnosed have concerns with fertility, weight gain and premature 
menopause, which all lead to psychological distress (Howard-Anderson et al., 2012). However, 
the decreases in quality of life associated with this distress is generally greatest during treatment, 
but 10 years post-diagnosis, life satisfaction and quality of life return to near-normal levels 
(Kessler, 2002).  Additionally, greater social and emotional support increases quality of life, as 
well as missing fewer days of work and remaining employed after diagnosis (Howard-Anderson 
et al., 2012). All of these factors contribute to the interaction of social and psychological health 
with physical function. By identifying the dysfunctions common in a breast cancer survivor 
population, it may be possible to help mitigate this initial drop in quality of life and shorten the 
time period to reach ‘normal’ levels of life satisfaction. 
2.2.2 Exercise as Rehabilitation for Breast Cancer Survivors  
Exercise can enhance function across body systems.  Resistance training is generally used 
to increase or maintain strength and muscle tone, and aerobic training increases endurance and 
aerobic capacity (Herrero et al., 2006). Although beneficial for breast cancer survivors, decreases 
in physical activity levels are prominent relative to pre surgery levels (Devoogdt et al., 2010).   
Exercise has additional effects such as increased quality of life, range of motion and grip 
strength. Exercise does not appear to decrease lymphedema, but has positive effects on quality of 
life in moderate doses (Courneya et al., 2014; Hayes et al., 2009; McKenzie and Kalda, 2003). 
However, by starting exercises immediately after surgery, breast cancer survivors recover more 
range of motion. Although significant, the differences were modest: 3° in flexion (164° for 
delayed start compared with 167° for immediate start) and 11° in abduction (145° and 154° 
respectively). No differences in the two groups existed in development of secondary symptoms, 
or recovery of grip strength (Bendz and Fagevik Olsén, 2002).  
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2.2.3 Additional therapies following Breast Cancer Diagnosis and Treatment 
Beyond exercise, other modalities have been explored for the rehabilitation of breast 
cancer survivors. Ultrasound, acupuncture and complimentary and alternative medicine (CAM), 
among others, have all been suggested to improve function in this population. Both ultrasound 
and acupuncture have been utilized to decrease the effects of lymphedema. Ultrasound is used to 
determine the severity of the issue and identify problematic regions. With this, corsets can be 
fitted to help decrease tissue swelling (Hansdorfer-Korzon et al., 2016), or accurately place nerve 
blocks to decrease pain (Wijayasinghe et al., 2016). Further, following acupuncture survivors 
had a decrease in lymphedema of up to 50% (compared to 25% with those taking medication), 
and an overall increase in quality of life (Yao et al., 2016), although no change in function was 
observed. Complimentary and alternative medicine combines spiritual, medical and physical 
(chiropractic, massage) aspects to improve the quality of life of survivors. The theory behind this 
strategy is to holistically help both the mind and body heal from the disease. However, an 
increase of arm function has yet to be observed (Kang et al., 2014). Any effects from 
complimentary and alternative medicine, cannot be targeted to one therapy as a combination of 
therapies typifies this strategy. Well-rounded recovery of the breast cancer survivor population is 
likely dependent on a combination of additional modalities (ultrasound, acupuncture, 
chiropractic, massage) and exercise.  
2.3 Additional Symptoms Associated with Breast Cancer Survivorship 
2.3.1 Lymphedema 
 Lymphedema is a common complication following axillary node dissection in breast 
cancer treatments. It is defined as a retention of fluid in the arm which ultimately causes swelling 
of the ipsilateral arm. This hinders many activities of daily living, and ultimately reduces quality 
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of life among breast cancer survivors. Additionally, survivor age (>60 years), number of nodes 
dissected, radiation therapy, and higher BMI may predispose breast cancer survivors to 
developing lymphedema (Hack et al., 2010; Sakorafas et al., 2006).  
 The presence of lymphedema is generally measured one of two ways. The first is a 
measurement of the arm circumference, which is compared to the non-affected limb. A 
difference greater than 2cm is considered indicative of lymphedema (Ahmed et al., 2006). The 
second technique is to measure the volume of the arm. Volume increases greater than 20% 
indicates lymphedema (Sakorafas et al., 2006; Swedborg and Wallgren, 1981). Reported 
prevalence varies from 6% to 70%, developing from a few months to 20 years post-surgery 
(Ahmed et al., 2006; Petrek et al., 2000; Rietman et al., 2003; Sakorafas et al., 2006; Schmitz et 
al., 2010; Sugden et al., 1998; Swedborg and Wallgren, 1981). For many, arm functional deficits 
are not a lifestyle priority, therefore lymphedema may go unreported (Sakorafas et al., 2006).  
The swelling in the arm can cause severe disability for breast cancer survivors. Survivors 
with clinically diagnosed lymphedema scored lower on several quality of life measures, such as 
body pain and mental health (Velanovich and Szymanski, 1999). Due to the swelling and pain 
that characterizes lymphedema, daily tasks can be difficult. Recently, focus has shifted to 
exercise programs to mitigate the effects of lymphedema. Many programs were able to increase 
range of motion of the arm, but there were not any significant changes in reducing lymphedema, 
or decreasing onset (Chan et al., 2010). Although the true prevalence is not known, it is clear that 
lymphedema has an impact on function and quality of life. 
2.3.2 Pain  
 Pain is a common post treatment symptom for many breast cancer survivors and it is  
present in 31-61% of breast cancer survivors, with a positive occurrence being pain in the neck, 
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arm and/or shoulder at least twice a week (Lauridsen et al., 2008; Tasmuth et al., 1995). In a 
survey of 316 breast cancer survivors, the mean pain score was 21.6 out of 78, indicating that 
pain is present but generally not debilitating. Further, it is prevalent in 55-61% of breast cancer 
survivors who receive mastectomies and radiation, and 24-28% of those who receive breast 
conserving therapy (Lauridsen et al., 2008; Shamley et al., 2012; Tasmuth et al., 1995). In 
particular, pain is often greater in younger breast cancer survivors, and persons who had 
recurrences of the disease (Tasmuth et al., 1995). It has been suggested that the younger patients 
have greater neural disruption which increases pain (Downing and Windsor, 1984). It is most 
often identified via self-reporting through a visual analog scale or questionnaire, reporting 
discomfort in ipsilateral shoulder, arm axilla, breast, neck and/or chest wall.  While the whole 
body is negatively affected following surgery, chemotherapy and/or radiation, damage occurs to 
muscles and other soft tissues most often in the upper extremities and anterior chest.  However, 
pain does not predict arm morbidity well, including outcomes such as loss of range of motion or 
lymphedema (Hack et al., 2010). Variable pain affects a large portion of breast cancer survivors 
and must be considered when addressing the potential physical limitations of this population. 
2.3.3 Fatigue 
 Fatigue is common during cancer treatment. It is generally recognized as the state of 
weariness after a period of mental or physical exertion and is characterized by a decreased 
capacity for work and reduced efficiency to respond to stimuli. Fatigue is common among many 
cancer patients, and affects everyday tasks. Stasi et al., (2003) found a strong link between 
fatigue and treatments for cancer, occurring in 80-96% of patients receiving chemotherapy, and 
60-93% of patients receiving radiation therapy. Fatigue was indicated as a preventative agent for 
completing daily tasks by 91% of cancer survivors. Although more prominent during treatment, 
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25% of survivors stated fatigue as an ongoing symptom (Stasi et al., 2003).  These levels of 
fatigue are consistent in the breast cancer population (Hsieh et al., 2008; Mock et al., 2005).  
To mitigate levels of muscular fatigue, exercise interventions have been implemented. 
Breast cancer survivors who had received surgery and radiation or chemotherapy had the greatest 
reduction in fatigue when participating in an individualized exercise program (Hsieh et al., 
2008). Breast cancer survivors were instructed to focus more on aerobic exercises to combat 
fatigue, with the addition of resistance training and flexibility to include a well-rounded exercise 
program. This whole body approach leads to improvements in both cognitive and muscular 
fatigue symptoms (Hsieh et al., 2008). Similarly, Mock et al., (2005) implemented a general 
home-based walking exercise protocol. Participants who exercised more than 60 minutes a week 
(in 3 sessions or more), had significantly less fatigue symptoms following the exercise program. 
Fatigue was not completely diminished, but participants who adhered to the protocol reported 
approximately 40% less fatigue, as determined by the Piper Fatigue Scale (Mock et al., 2005). 
Although both cognitive and muscular fatigue continues after treatment, they may be partially 
mitigated with proper attention.  
2.4 Primary Functional Deficits in the Breast Cancer Survivor Population 
2.4.1 Strength 
 Strength in the breast cancer survivor population is often quantified by grip strength as a 
surrogate for upper arm strength. Differences greater than 10% between affected and unaffected 
arm existed in 20-43% of survivors (Kuehn et al., 2000; Rietman et al., 2004; Swedborg and 
Wallgren, 1981). Grip strength has also been used to compare pre and post-surgical treatment. 
Combined grip strength decreased 2 weeks postoperatively (74kg from 78kg (p<0.05), but 
returned to preoperative levels within the first month. However, at a 2-year follow up grip 
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strength was 73kg, lower than preoperative measures of 78kg  (Bendz and Fagevik Olsén, 2002). 
It is important to know deficits in strength to better determine which tasks may be difficult. 
Certain muscle groups are affected more in the breast cancer survivor group due to the 
localization of the cancer. Merchant et al., (2008), investigated the strength, power and 
endurance of muscles of the affected limb and compared that to the unaffected limb. Flexors 
were not significantly different, likely due to the high variability in strength measurement. A 7% 
decrease in extensor strength was measured on the affected side compared to the unaffected side, 
with a 6% decrease in protractor and 4% decrease in retractor strengths on the affected side and 
unaffected sides, respectfully (Merchant et al., 2008).. Harrington et al (2013) measured strength 
isometrically in all fundamental shoulder exertions, and overall strength decreased compared to 
the control group. The breast cancer survivor group had on average, 20- 31.2% less strength 
compared to healthy controls in each fundamental shoulder exertion (Harrington et al., 2011). A 
negative relationship (r=-0.58) existed with decreased strength in the affected limb, and self-
reported disability which was determined based on DASH questionnaire (Harrington et al., 
2013). Survivors reported more disability when a decrease of strength was present. Current 
literature utilizes multiple methods to measure strength and is focused more heavily on strength 
measures such as grip strength, as they are easily attainable and performed more often in a 
clinical setting. A focus on shoulder exertions will provide a picture of the deficits at the affected 
shoulder and provide guidance to limit any compensations that may be occurring.  
2.4.2 Range of Motion 
Range of motion is reduced in breast cancer survivors, and varies depending on the 
treatment used. Reduced arm function was reported in 51% of breast cancer survivors in a recent 
self-reported survey (Sugden et al., 1998). Mastectomy patients reported reduction more often 
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(77%) than those with breast conserving therapy (33-39%), and reduction in flexion, abduction 
and external rotation was more prominent in patients treated with mastectomies (Ebaugh et al., 
2011; Harrington et al., 2013; Lauridsen et al., 2008; Nesvold et al., 2008; Sugden et al., 1998). 
Adding radiotherapy to a more invasive surgery technique resulted in increased reduction in 
abduction with external rotation and adduction with internal rotation, compared to radiation 
therapy and breast conserving therapy (Lauridsen et al., 2008; Sugden et al., 1998; Thompson et 
al., 1995).  
There have been many different attempts to quantify reduction in range of motion but 
they have yielded inconsistent findings. A minimum of 120° in abduction is necessary to 
complete daily tasks (Badley et al., 1984). However, in current literature impairment is 
sometimes determined by a 10° loss in range of motion compared to the unaffected limb (Kuehn 
et al., 2000).  Reduction in range of motion has been reported in 1-67% of survivors (Ernst et al., 
2002; Lee et al., 2008; Tengrup et al., 2000; Voogd et al., 2003). Various fundamental shoulder 
movements appear to be affected differently. A study involving 396 breast cancer survivors 
reported mean restrictions of 21° in abduction, and 12° in forward flexion compared to the 
unaffected arm (Kuehn et al., 2000). Similar results emerged from smaller studies focused on 
surgical patients receiving an adjuvant therapy. Rietman et al. (2004) reported forward flexion of 
158.9° in the non-affected side, and 153.2° on the affected side (p=0.004), abduction of 164.1° 
and 156.6° respectively, and external rotation of 63.5° and 57.3° (Rietman et al., 2004). 
However, only 6-16% of persons with lower ranges of motion were considered impaired (greater 
than 20° reduction in range of motion) 2.7 years after surgery (Rietman et al., 2004). A second 
study by Reitman et al. (2006) involving 181 participants tested pre-surgery and 2 years post-
surgery to determine residual deficits revealed forward flexion was 172.4° pre surgery and was 
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reduced by 4.4° two years after the surgery, while abduction was 168.0° and decreased by 16.2°, 
and external rotation was 67.7° - 5.9° less post-surgery (Rietman et al., 2006).  
This reduction in range of motion is thought to be potentially mitigated through breast 
reconstruction techniques, including the latissimus dorsi flap reconstruction technique. Garusi et 
al., (2016) reported more than 90% of patients recovered over 80% of normal range of motion in 
extension, flexion and internal/external rotation. However, 75% of patients only recovered 60-
80% of normal range of motion in abduction (Garusi et al., 2016). Residual loss in range of 
motion has implications on productivity. Combined with presence of pain or lymphedema, 75% 
of women presented with one or more of those symptoms and had an associated reduced capacity 
to continue working in their previous roles (Quinlan et al., 2009). Overall, range of motion is 
affected differently in all breast cancer survivors, but it is important to quantify the range of 
motion loss to determine rehabilitation strategies, and work capacity.  
2.5 Relevance to Current Research  
It has been established that changes to upper limb function occur after breast cancer 
treatment.  Strength and range of motion may be decreased in the affected arm, but the 
magnitude of this decrease is inconclusive. Varied populations and measurement techniques 
likely attribute to this uncertainty. Further, the muscle activation patterns of this population are 
variable, with increased muscular activity necessary to complete the same tasks as a healthy 
population. There has been no research, to date, on the differences between those with high and 
low self-reported physical function scores. By exploring the differences in these two groups 
more insight can be provided into the variability in this population, and why these differences in 






 Ten adult female breast cancer survivors participated [age; 58.1 ± 10 years, height; 
163.6cm ± 6.8cm, weight; 83.2 ± 29.0kg]. Survivors were 3 months post-treatment, but no more 
than 2 years. This ensured the survivors had time to heal from adjuvant therapy, but did not seek 
additional therapy that may have contributed to increases in function. Additionally, radiation 
therapy has shown to continue to affect tissue for up to two years following last treatment 
(American Cancer Society, 2016).  Breast cancer survivors must have: a) undergone any form of 
surgical procedure for breast tumour removal; b) received any form of radiation or 
chemotherapy; and c) had any form of breast cancer pathology (i.e. from Stage I – IIIa). Breast 
cancer survivors were excluded from participation if they had bilateral cancer, metastases, upper 
arm dysfunction that preceded cancer treatments, barium swallow within 3 weeks of 
participation, and women who were or suspected they were pregnant. Survivors screened for 
participation are detailed in Figure 1. Informed consent was obtained prior to experimental data 
collection and the study was reviewed by and received ethics clearance through a University of 




Figure 1: Consort diagram detailing breast cancer survivors who were screened for participation 
and reasons for exclusion 
 
3.2 Instrumentation  
3.2.1 Motion Capture  
  Three-dimensional kinematic data were collected using an 8-camera optoelectronic 
VICON MX20 Motion capture system (VICON, Oxford, UK) at 50Hz. Prior to participant 
arrival, the collection space was calibrated using Vicon Nexus 1.8.5 software. The global origin 
was set with the positive global Z-axis being upwards, the positive X-axis being to the right and 
the positive global Y-axis in the anterior direction. This was rotated into ISB standards following 
collections (Wu et al., 2005). Twenty-one reflective markers were placed on the torso and both 
upper extremities over anatomical landmarks (Figure 2). Additionally, two cluster sets (upper 
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arm and forearm) were attached on each arm. The upper arm and forearm clusters were used to 
mathematically reconstruct trials where original bony landmark data were missing (Howarth and 
Callaghan, 2010). A static calibration frame was taken with the participant in anatomical position 
to establish a relationship between anatomical landmarks and the marker clusters.  
 





3.3 Experimental Protocol 
Five participants visited the lab on two separate occasions, with a minimum of 16 weeks 
between visits. The other five participants were assessed on a single occasion. Monthly 
questionnaires were administered to identify any rehabilitation and physical activity completed 
between visits (Godin and Shephard, 1997). The time between collections represented a period 
of normal activity to capture the change in functionality over time without specific intervention. 
The collection protocol (Figure 3) during each visit was identical.  
Figure 3: Overview of Laboratory Collection Protocol 
 
3.3.1 General Laboratory Collection Protocol Overview .  
Prior to experimental data collection, the participants reviewed the information consent 
form and provided informed consent. Participants completed a general information form 
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(Appendix A). Within this form, participants were asked to detail diagnosis, treatment types and 
length, current physical activity levels, co-morbidities, present medications, and history of upper 
extremity discomfort prior to diagnosis. Following this, basic anthropometric data were collected 
by the researcher, including height, weight, and age. 
Each visit to the lab began with participants completing the three standardized 
questionnaires followed by a dual-energy x-ray absorptiometry (DXA) scan. Following this, 
electrode placement took place for both the affected and unaffected limbs. Participants then 
performed one round of MVCs for each muscle, for a total of 14 exertions. Voltage output was 
monitored and in trials which participants did not reach a plateau, a second MVC was taken. This 
approach was used to avoid pain and fatigue in this clinical population due to multiple trials. 
There was a minimum of two minutes of rest between each exertion to avoid fatigue (Chaffin, 
1975). Extra time was given between trials at the participant’s request, and for one participant 
positions were altered by decreasing the elevation of the arm when pain was present. This 
allowed the participant to perform maximally, as pain was no longer a hindrance to performance.  
 Next, strength measures were collected. After each strength measure (and all trials to 
follow) a rating of perceived discomfort (RPD) and rating of perceived exertion (RPE) value was 
taken and two minutes of rest was given, with extra time at the participant’s request. To avoid 
fatigue, only one strength trial was collected for each posture for both the affected and unaffected 
limbs (described in Table 3 below). Position and force were monitored. Any variation in position 
indicated a second trial needed to be collected. The force was also observed for a distinct 
plateau; when this was not reached a second trial was also collected. Reflective markers were 
placed on the participant following these trials. 
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Next, the participant performed maximal range of motion trials. One trial of each active 
range of motion (described in section 3.4.4) was taken for both the affected and unaffected limb, 
for a total of 12 trials per participant.  If participants were unable to reach their maximum in five 
seconds, a second trial was performed to ensure the entire range was collected. 
3.3.2 Non-Intervention Period  
 During the 16 weeks between laboratory visits, usual care took place. However, activity 
of participants was monitored by asking participants to fill out the modified Godin questionnaire 
at the end of every month via email or phone call (Godin and Shephard, 1997).  
3.4 Experimental Measures  
3.4.1 Questionnaires 
 Questionnaires were used to provide insight into quality of life. These questionnaires 
were given to the participants both at the baseline collection and the follow up visit (when 
applicable). The three questionnaires that were administered (Appendix F) are the Functional 
Assessment of Cancer Therapy – Breast Cancer (FACT-B) (Cella, 2007), Rand-36 Health 
Survey short form (RAND 36/SF 36) (Hays et al., 1993) and the Disabilities of the Arm, 
Shoulder and Hand (DASH) (Hudak et al., 1996). FACT-B is a standardized quality of life 
survey wherein participants were asked to use a rating scale to quantify their physical well-being. 
SF 36 is also a quality of life survey, but includes additional questions on physical functioning. 
Finally, the DASH questionnaire is related specifically to the upper extremity and asks 
participants to respond to questions regarding symptoms relating to their physical capabilities. 
Each questionnaire was scored as outlined and validated by the creators. For FACT-B and SF-36 
higher scores indicated belter quality of life/physical functioning. For the DASH questionnaire a 
lower score indicated higher quality of life/physical functioning.  
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In order to account for physical activity that may induce changes in upper extremity 
function between visits, a modified version of the Godin Leisure Time Activity questionnaire 
(Appendix A) was given to participants at baseline and follow up, as well as monthly via email 
or phone call. Additional questions were added to incorporate possible physical therapy the 
participant may be receiving. This data may allow future grouping of participants based on their 
activity levels. As physical therapy may have implications on function in this population, 
characterizing the differences in participants’ activity level between visits may help clarify the 
potential origins of observed changes.  
3.4.2 Rating of Perceived Exertion/Discomfort 
 Rating of Perceived Exertion (RPE) is a qualitative measure that was implemented to 
both monitor participants as they complete tasks, and track fatigue. Participants verbally 
provided a rating between 0 and 10 (Borg, 1998) (Figure 4 Below). Participants were instructed 
to choose any value, and were not restricted to whole numbers. They were reminded that this 
pertains solely to the shoulder and not to the whole body. RPE was recorded at the end of every 
trial to ensure participants are receiving adequate rest and are not performing tasks in a fatigued 
state. Rating of Perceived Discomfort (RPD) can provide insight into movements which cause 
discomfort. RPD was taken at the same time as RPE. Similar to RPE, RPD can help ensure 
adequate rest was given between trials.  Additionally, RPD provides insight into which tasks 
prove to be the most challenging for participants. For both scales, a baseline score was taken 





Figure 4: Modified Borg Scale – Rating of Perceived Exertion (Borg, 1998) 
3.4.3 Strength Measures 
 Maximum voluntary strength was measured for several fundamental shoulder exertions 
(flexion/extension, abduction/adduction, and internal/external rotation). Arm positions were 
chosen to replicate maximal strength outputs as described in previous literature (Hughes et al., 
1999; Stobbe, 1982) (Table 2). A cuff was placed on the upper arm and attached to a 6 degree of 
freedom force transducer (MC3A, AMTI, Watertown, MA, USA) with a chain (Figure 5). The 
participants were strapped to a chair to decrease potential compensations, and increase 
replicability. The force cube was positioned to ensure that the chain was pulled tight and force 
exerted is in the z axis, while the x and y axis forces were minimized. Strength measures were 








in the coronal plane 
Abduction Abducted 30
° 
in the coronal plane 
Flexion Abducted 30
° 
in the sagittal plane 
Extension Abducted 60
° 
in the sagittal plane 
Internal Rotation Abducted 90
° 
in the coronal plane, elbow flexed 90
°
, forearm neutral 
External Rotation Abducted 0
°
 in the coronal plane, elbow flexed 90
°
, forearm neutral 
 
 
Figure 5: Example of a flexion strength trial with cuff above the elbow to ensure force was 




3.4.4 Range of Motion 
 Maximal range of motion trials for each plane of motion, for the affected and unaffected 
shoulders, were completed.  Participants moved from a neutral position to their maximum in 
each fundamental shoulder movement (flexion/extension, abduction, internal/external rotation 
and scapular plane elevation). For all motions, a pole was placed in a location that ensured the 
motion remained in the desired plane (Figure 6).  
 
Figure 6: Example of abduction range of motion trial with a pole to guide movement 
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3.5 Data Analysis  
3.5.1 Kinematic Data Processing 
 Raw 3D kinematic marker position data were labelled, and missing markers were pattern-
filled by reconstructing the marker trajectory using markers present in the trial using Vicon 
Nexus 1.8.5 (Vicon, Oxford, UK). Kinematic data were dual pass filtered with a second order, 
low pass Butterworth filter with a cut-off frequency of 4Hz.  
 Joint centres and segments were calculated in accordance with previous literature. The 
humeral head was located by adding 60mm in the negative direction of the y-axis of the torso 
(which connects the centre of SS and C7 and the centre of XP and T8, pointing upwards) from 
the acromion marker (Nussbaum and Zhang, 2000).  The joint centres, upper arm segment and 
torso segments and  local coordinate system for each segment were defined according to ISB 
recommendations, described in Table 3 (Wu et al., 2005).  
Table 3: Description of segments and local coordinate systems (Wu et al., 2005) 
 Upper arm Torso 
Positive y axis The line created between the 
humeral head and the joint centre of 
the elbow (1/2 way between lateral 
and medial epicondyles), pointing 
upwards 
The line created by the centre of C7 
and SS and the centre of T8 and 
XP, pointing upwards 
Positive x axis Cross multiplication of the y axis 
and temporary Z axis (line formed 
between the lateral and medial 
epicondyles), pointing forwards 
** X is created last for this axis 
system 
A true X axis is then formed by 
crossing the Y and Z axes, pointing 
forwards  
Positive z axis A true Z axis is then formed by 
crossing the Y and X axes, pointing 
to the right 
Cross multiplication of the y axis 
and temporary X axis (line formed 





The relative rotation matrices were found by multiplying the distal segment (humerus) by 
the transpose of the proximal segment (thorax). Humerothoracic joint descriptions were based on 
the Euler YXY’ rotation sequences (Wu et al., 2005). The clinically relevant rotations are 
described below in Table 4. For each range of motion trial maximum and minimum angles for 
rotations about each axis were extracted using a custom Matlab TM R2016b program (Mathworks 
Inc., USA). Finally, the range of motion was determined by subtracting the minimum from the 
maximum for each rotation (Hall et al., 2011). 




el: Glenohumeral plane of elevation (0 is pure abduction, 
90 is forward flexion) 
e3: internal rotation (positive); external rotation (negative) 
e2:elevation (negative) 
 
3.5.2 Strength Data 
 Force data were smoothed using a low pass, second order, dual pass Butterworth filter, 
with a cut-off frequency of 6 Hz. A particular joint strength was assumed to be the maximum 
force output, from each respective strength trial, and was extracted to use for analysis using a 
custom MatlabTM R2016b program (Mathworks Inc., USA). 
3.5.3 Statistical Analysis 
 Prior to any statistical analyses, data were screened for outliers using Grubb’s tests 
(Grubbs, 1950). The confidence interval was set to 95%, and with only ten observations per 
variable, any experimental data point with an absolute z-score above 2.176 was removed and 
considered an outlier.  
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For all strength and range of motion trials, Pearson correlation coefficients (r) were 
computed for all dependent variables. DASH scores were viewed as the independent variable, 
with strength (n=6) and range of motion (n=6) as the dependent variables. A correlation 
coefficient of less than 0.3 was considered weak, 0.3 -0.7 was considered moderate, and anything 
above 0.7 was considered strong (Vincent and Weir, 2012). 
Two comparisons were made using t-tests. Firstly, the data were split between high and 
low DASH scores, for each variable. Group A refers to the groups with higher QOL as defined 
by DASH scores (score of 10 or lower), and group B as those with a higher DASH score (greater 
than 10). Five participants were allocated into each group. Additionally, affected and unaffected 
limbs were compared for each variable. Independent sample, one-tailed, t-tests were completed 
for each variable. The p-value was originally set for 0.05. A Shapiro-Wilk Test was used to 
assess normality of all variables. Any variables that did not fit within a normal distribution were 
discarded from t-tests to ensure no false positives were considered (Shapiro and Wilk, 1965). 
Normality tests were completed using JMP 13 (SAS Institute Inc., Cary, NC). A Bonferroni 
correction was completed, altering the p-value to 0.03 for strength, range of motion and EMG 
data. All t-tests were completed using a custom Matlab TM R2016b program (Mathworks Inc., 
USA).  Finally, effect sizes were calculated for strength and range of motion data, using the 
following equation, where M represents mean, and SD represents standard deviation of each of 
the groups. Effect sizes of 0.2-0.5 were considered small, 0.5-0.8 were moderate and above 0.8 
were considered large effect sizes (Cohen, 1988). 
Cohen’s d = (𝑀1 −𝑀2) √((𝑆𝐷1
2 + 𝑆𝐷2





Out of the ten participants, five were classified as high physical functioning and five as 
low physical functioning. These two groups were equally split on the basis of DASH scores. 
Using the SF-36 questionnaire, the physical functioning section of the questionnaire is reported 
in the table below and showed a significant difference between the two groups (Table 5), such 
that participants with higher physical functioning scored 49% higher than that of the group with 
lower physical functioning. The FACT-B questionnaire showed no differences between low and 
high physically functioning participants (p=0.11).  
Table 5: Questionnaire results (A higher score indicates higher QOL for FACT-B and SF-36, 







DASH  5 (± 3.9) 30.67 (± 15.6) 0.003 
FACT-B  122.4 (± 13.8) 105.2 (± 16.3) 0.110 
SF-36  94 (± 10.8) 63 (± 12.5) 0.007 
 
4.2 Demographics  
 The two groups were compared based on demographics. No significant differences 
existed for stage, side affected, whether dominant limb was affected, and surgical treatment. 
Notably, significant differences between groups existed in the adjuvant therapy received. The 
group with higher physical function scores received a combination of both chemotherapy and 
radiation (n=4) and just chemotherapy (n=1) for adjuvant therapy, and those with lower physical 





Table 6: Qualitative demographics of each breast cancer survivor group. Participants were tallied 







1 2 3 
2 1 2 
3 2 0 
Side 
Right 3 3 
Left 2 2 
Dominant 
Affected? 
Yes 3 3 
No 2 2 
Surgery 
Mastectomy 2 2 
Lumpectomy 3 3 
Adjuvant 
Therapy 
Radiation 0 4 
Chemotherapy 1 0 
Both 4 1 
 
 Comparison quantitative anthropometric and medical history data were also collected 
(Table 7). There were no statistical differences between the two groups for all variables 
examined. Although not statistically significant, there was a trend in both % body fat and 
affected limb % fat with the 10 participants collected (p=0.07-0.08), warranting further 
investigation, specifically that those with lower body fat percentage had higher self-reported 
physical function. There was 8% difference in total % body fat, and 13% difference in affected 
limb % fat. For both variables, the group with higher physical function scores had lower body fat 
% and lower affected limb % fat than that of the group with lower physical function scores. 
Additionally, there was a moderate negative correlation between DASH scores (where a lower 
score represents higher physical function) and mild physical activity/week (r = -0.54), where 1.2 








Table 7: Quantitative demographics of each breast cancer survivor group 




p-value Cohen’s d 
Physical Activity 4 (± 2.8) times a 
week 
2 (± 1.2) times a 
week 
0.18 0.92 
Time since Treatment 9.8 (± 6.2) 
months 
8.6 (± 3.8)  
months 
0.72 0.23 
Age 57 (± 4.8) years 
old 
59.2 (± 14.2) 
years old 
0.75 0.21 
Height 161.6 (± 2.0) cm 165.5 (± 9.5) cm 0.39 0.57 
Weight 69.0 (± 16.2) kg 97.5 (± 33.5) kg 0.12 1.08 
% Body Fat 40.3 (± 7.7) % 48.5 (± 5.0) % 0.08 1.26 
Affected Limb Fat Mass 1644.78 (± 
836.8) g 
2431.3 (± 577.3) 
g 
0.12 1.09 
Affected Limb Lean 
Mass 
1850.3 (± 145.0) 
g 
1741.1 (± 344.5) 
g 
0.53 0.41 
Affected Limb % Fat 43.2 (± 11.1) % 56.3 (± 8.7) % 0.07 1.31 
 
4.3 Strength 
 Strength was analyzed in two ways. For each strength measure the correlation with 
DASH scores as well as a comparison between the two groups was performed (Tables 8 and 9). 
Each strength measure was below that of a 50th percentile adult female, indicated by the green 
line on Figures 7-12. 
4.3.1 Group Comparisons for Strength Measures 
 The affected limb of the two groups (low and high physical function scores), as described 
above were compared (Table 8).  Abduction (Figure 7), adduction (Figure 8), extension (Figure 
9) and flexion (Figure 10) exhibited significantly different strengths between the two groups. The 
largest strength difference was in flexion, with the group with high physical function scores 
having 51.7% higher strength than the group with lower physical function scores. Extension 
strength was 38.9% higher in the group with higher physical function scores compared to the 
group with lower physical function scores. Abduction and adduction strengths were 32.3 and 
33.5% higher in those with higher physical function scores than those with lower physical 
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function scores. Of the measures collected, external rotation (Figure 11) and internal rotation 
(Figure 12) were not decreased in the group with lower physical functioning despite having 
differences of 26.8 and 16.3%, respectively (p > 0.03). However, external rotation strength had a 
moderate effect size of 0.63, where internal rotation strength had a small effect size of 0.32.  
Table 8: Mean (SD) strength measures for each group (Nm). Percent change represents the 
increase from low physical function to high physical function. 
  
 
Figure 7: Abduction strength for both high and low physical function individuals, in both the 
affected and unaffected limbs. Overall means are indicated with a thick red line, and 50th 









p-value Cohen’s d 
Abduction 16.47 (± 4.71) 12.45 (± 4.77) 32.3% 0.03 0.85 
Adduction 17.60 (± 7.43) 13.18 (± 4.50) 33.5% 0.003 0.72 
Extension 21.16 (± 5.80) 15.24 (± 7.11) 38.9% 0.03 0.92 
External 
Rotation 
24.44 (± 10.45) 19.28 (± 5.03) 26.8% 0.17 0.63 
Flexion 19.25 (± 5.27) 12.69 (± 6.91) 51.7% 0.004 1.07 
Internal 
Rotation 




Figure 8: Adduction strength for both high and low physical function individuals, in both the 
affected and unaffected limbs. Overall means are indicated with a thick red line, and 50th 
percentile strength of an adult female is indicated with the thick green line. 
 
 
Figure 9: Extension strength for both high and low physical function individuals, in both the 
affected and unaffected limbs. Overall means are indicated with a thick red line, and 50th 





Figure 10: Flexion strength for both high and low physical function individuals, in both the 
affected and unaffected limbs. Overall means are indicated with a thick red line, and 50th 
percentile strength of an adult female is indicated with the thick green line. 
 
 
Figure 11: External rotation strength for both high and low physical function individuals, in both 
the affected and unaffected limbs. Overall means are indicated with a thick red line, and 50th 





Figure 12: Internal rotation strength for both high and low physical function individuals, in both 
the affected and unaffected limbs. Overall means are indicated with a thick red line, and 50th 
percentile strength of an adult female is indicated with the thick green line. 
 
4.3.2 Limb Comparisons for Strength Measures 
 For all six strength measures there were no bilateral limb differences (p > 0.03; Table 9; 
Figures 7-12). On average, strength differed by approximately 2 Nm. However, individual 
participants’ unaffected limb was between 0 and 15 Nm higher than that of the affected limb 








Table 9: Mean (SD) strength measures for each limb (Nm). Percent change represents the 
increase from affected limb to unaffected limb. 
 
4.3.3 Correlation of DASH Scores and Strength  
 Correlation of DASH scores and strength of the affected limb was computed for all 
strength measures collected. One participant’s DASH score was identified as an outlier, and was 
thus was removed from all correlations.  A moderate negative relationship existed between 
flexion and DASH score (r = -0.50, Table 10) and extension and DASH score (r = -0.41). 
Further, moderate negative correlations were quantified for abduction and DASH score (r = -
0.45) and adduction and DASH score (-0.48). A 1Nm decrease in flexion strength, and a 1.2Nm 
decrease in extension strength represented approximately a 5 point increase in DASH scores 
(Figures 8, 9). Similarly, a 1.8Nm decrease in adduction strength, and a 1.3Nm decrease in 
abduction strength represented a 5 point increase in DASH scores. External and internal rotation 
showed a weak negative correlation with DASH scores (r=-0.24 and -0.25, respectively). It 
should be noted, however, that internal and external rotation included forces that may have been 
generated at the elbow, whereas the others were isolated to just shoulder strength.  
 
 
 Affected Unaffected Percent 
Change 
p-value Cohen’s d 
Abduction 14.46 (± 4.95) 14.65 (± 4.94) 1.3% 0.98 0.01 
Adduction 15.39 (± 6.25) 16.67 (± 6.15) 8.4% 0.71 0.08 
Extension 18.20 (± 6.87) 18.23 (± 6.95) -0.2% 0.76 0.002 
External 
Rotation 
21.86 (± 8.19) 21.13 (± 7.23) -3.5% 0.99 0.03 
Flexion 15.97 (± 6.75) 16.15 (± 6.53) 1.1% 0.71 0.01 
Internal 
Rotation 
17.53 (± 7.93) 18.15 (± 5.55) 3.5% 0.87 0.03 
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Table 10: Correlation of strength and DASH scores 
 
4.3.4 Comparison of Baseline and Follow-up for Strength Measures 
All strength measures were compared for the affected limb for five participants at 
baseline and follow-up (Table 11). All strength measures were statistically similar at baseline 
and follow-up (p>0.05, Table 11), although differences ranged from -18.8% (where baseline was 
higher than follow-up), to 32.3% (where follow-up was higher than baseline). Effect sizes were 
small for abduction, extension, external rotation and flexion (0.24-0.47), and moderate for 
adduction 0.72. Internal rotation had an insignificant effect size of 0.04.  
Table 11: Mean (SD) strength measures for baseline and follow-up (Nm). Percent change 
represents the increase from baseline to follow-up. 
 
4.4 Range of Motion 
 A relationship between range of motion and DASH scores for affected and unaffected 
limb was examined. Elevation angles were reported for all measures, except the two rotation 
angles (were axial rotation was reported). 





Abduction r2=- 0.2037 r=-0.45 0.19 
Adduction r2=- 0.2318 r=-0.48 0.27 
Extension r2=- 0.1676 r=-0.41 0.22 
External Rotation r2=- 0.06 r=-0.24 0.19 
Flexion r2=- 0.2295 r=-0.50 0.18 
Internal Rotation r2=- 0.0635 r=-0.25 0.51 




Abduction 13.80 (± 5.62) 16.43 (± 5.61) 19.1% 0.24 0.47 
Adduction 14.14 (± 8.10) 18.72 (± 3.91) 32.3% 0.14 0.72 
Extension 18.60 (± 7.80) 17.08 (± 4.42) -8.8% 0.64 0.24 
External Rotation 24.53 (± 10.34) 21.35 (± 3.76) -14.9% 0.73 0.41 
Flexion 15.06 (± 9.19) 12.69 (± 3.73) -18.8% 0.70 0.34 
Internal Rotation 19.28 (± 8.56) 19.61 (± 8.22) 1.7% 0.48 0.04 
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4.4.1 Group comparisons for Range of Motion Tasks 
 Statistical differences existed between participants with low and high physical function 
scores for internal rotation (p = 0.02). The group with high physical function scores had 1.9 
times more internal rotation than those with low physical function scores (Figure 13). It is 
notable that the group with higher physical function scores had consistently higher range of 
motion (ranging from 11.6-79.8%). There were no statistical differences between groups for any 
other range of motion tasks (Figures 14-18), however the effect size for flexion was large (0.94) 
and all other effect sizes were moderate (ranging from 0.42-0.57) (Table 12).  
Table 12: Mean range of motion (SD) for each group (Degrees). Percent change represents the 
increase from low physical function to high physical function. 








Abduction 138.39 (± 28.33) 123.96 (± 25.25) 11.6% 0.42 0.54 
Extension 28.30 (± 18.31) 20.91 (± 16.94) 35.4% 0.53 0.42 
External Rotation 28.47 (± 28.77) 15.84 (± 13.07) 79.8% 0.40 0.57 
Flexion 151.49 (± 31.10) 125.42 (± 24.18) 20.8% 0.18 0.94 
Internal Rotation 38.84 (± 14.34) 13.32 (± 12.65) 191.7% 0.02 1.89 
Scapular Plane 
Abduction 





Figure 13: Internal rotation range of motion for both high and low physical function individuals, 
in both the affected and unaffected limbs. Overall means are indicated with a thick red line. 
 
Figure 14: Abduction range of motion for both high and low physical function individuals, in 




Figure 15: External rotation range of motion for both high and low physical function individuals, 
in both the affected and unaffected limbs. Overall means are indicated with a thick red line. 
 
Figure 16: Extension range of motion for both high and low physical function individuals, in 




Figure 17: Flexion range of motion for both high and low physical function individuals, in both 
the affected and unaffected limbs. Overall means are indicated with a thick red line. 
 
Figure 18: Scapular plane abduction range of motion for both high and low physical function 




4.4.2 Limb Comparisons for Range of Motion Tasks 
 There were no statistical differences between affected and unaffected limbs in range of 
motion (p > 0.03). On average, range of motion differed by 5° between affected and unaffected 
limbs (Table 13). Participants differed between 0 and 40° for range of motion across the different 
movements collected. However, external rotation had a moderate effect size of 0.42, with a 55% 
increase in range of motion on the unaffected limb compared to the affected limb (Table 13). 
Table 13: Mean range of motion (SD) for each limb (Degrees). Percent change represents the 
increase from affected limb to unaffected limb. 
 
4.4.3 Correlation of DASH Scores and Range of Motion  
 Several of the fundamental shoulder motions measured had a linear correlation with 
DASH scores. As previously stated, one participant was excluded from all correlations as their 
DASH score was identified as an outlier. Internal rotation had the strongest linear, negative 
relationship (r = -0.60, Table 14), such that higher range of internal rotation was associated with 
lower DASH scores. Flexion and abduction had moderate, negative relationships (r = -0.45 and -
0.30 respectively). A 4.5° decrease in internal rotation range of motion, a 6.4° decrease in flexion 
range of motion or a 3.6° decrease in abduction range of motion represented approximately a 5 
point increase in DASH scores. Scapular plane abduction had a weak negative relationship with 




Abduction 131.17 (± 26.42) 132.61 (± 25.54) 1.1% 0.90 0.01 
Extension 24.61 (± 17.08) 21.28 (± 11.44) -15.63% 0.91 0.14 
External Rotation 22.16 (± 23.00) 34.34 (± 32.99) 55.0% 0.34 0.42 
Flexion 138.46 (± 29.64) 133.00 (± 34.10) -4.1% 0.71 0.04 
Internal Rotation 26.08 (± 18.54) 31.02 (± 25.68) 18.9% 0.63 0.17 
Scapular Plane 
Abduction 
132.46 (± 29.78) 136.36 (± 33.20) 2.9% 0.79 0.03 
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DASH scores (r = -0.19). Finally, both external rotation and extension were not correlated with 
DASH scores (r = 0.04 and r = -0.05, respectively).  
Table 14: Correlation of range of motion and DASH scores  
 
4.4.4 Comparison of Baseline and Follow-up for Range of Motion Tasks 
All range of motion tasks were compared for five participants at baseline and follow-up 
(Table 15). Extension range of motion increased by 112% from baseline to follow up (p=0.01, 
Table 15). All other range of motion tasks were not different at follow up compared to baseline. 
However effect sizes were moderate for scapular plane abduction, abduction and external 
rotation range of motion (0.29-0.68), with follow-up increasing by 4.7-44.4% from baseline. 
Internal rotation decreased by 73.8% from baseline to follow-up (effect size of 0.44) (Table 15).  
Table 15: Mean range of motion (SD) for baseline and follow-up (Degrees). Percent change 
represents the increase from baseline to follow-up. 
 
 





Abduction r2=- 0.0889 r=-0.30 0.44 
Extension r2=- 0.0026 r=-0.05 0.90 
External Rotation r2=- 0.0015 r=-0.04 0.92 
Flexion r2=- 0.2063 r=-0.45 0.22 
Internal Rotation r2=- 0.3615 r=-0.60 0.05 
Scapular Plane 
Abduction 
r2=- 0.0373 r=-0.19 0.62 




Abduction 141.78 (± 24.34) 154.83 (± 12.28) 9.4% 0.32 0.68 
Extension 32.24 (± 20.54) 68.19 (± 15.90) 111.5% 0.01 1.96 
External Rotation 28.03 (± 21.32) 40.46 (± 33.83) 44.4% 0.51 0.44 
Flexion 151.66 (± 24.87) 153.26 (± 12.20) 1.1% 0.90 0.08 
Internal Rotation 27.89 (± 16.14) 20.59 (± 17.16) -73.8% 0.51 0.44 
Scapular Plane 
Abduction 
139.08 (± 31.89) 145.58 (± 4.64) 4.7% 0.66 0.29 
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4.5 Rating of Perceived Discomfort 
 Rating of perceived discomfort was analyzed for each group as well as between 
unaffected and affected limb. 
4.5.1 Comparison of groups 
 There were no differences in RPD ratings of participants with high and low physical 
function scores during strength trials. Notably, internal rotation strength trials had the largest 
group difference. Perceived discomfort in the low physical function score group was 3.4/10, 
compared to 0.8/10 for the high physical function group. All other strength trials showed 
minimal group differences in reported discomfort. 
Statistical differences existed in the RPD between groups with high and low physical 
function scores for some range of motion trials. For the affected limb, participants in the group 
with high physical function scores perceived less discomfort during internal rotation and 
abduction relative to participants in the group with low physical function scores. External 
rotation, flexion, extension and scapular plane abduction showed no group differences. Overall, 
the high physical function group rated discomfort of range of motion tasks 0.5/10, while the low 
physical function group rated these motions 3/10. No differences occurred between groups when 
using the unaffected limb. 
4.5.2 Comparison of limbs 
 There were no statistical differences in RPD between the affected and unaffected limbs 
during strength trials. On average, participants rated strength trials with the affected limb 1.5/10, 
while the unaffected limb was rated 1/10.  
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 Differences existed in range of motion trials between the affected and unaffected limb. 
Flexion and abduction of the affected limb were perceived with higher discomfort than that of 
the unaffected limb (p<0.05). The unaffected limb was perceived with zero discomfort, while the 
affected limb averaged from 0.5-2 out of 10. Scapular plane abduction, extension and external 







The aim of this research was to quantify the upper limb function of acute breast cancer 
survivors with respect to strength and glenohumeral range of motion. Comparisons were made 
between high and low function breast cancer survivors (as determined by questionnaire scores) 
as well as between the affected and unaffected limbs. Each hypothesis was addressed with 
experimental data and the results are discussed below, as well as future work and contributions 
of this research. 
5.1 Hypotheses  
5.1.1 Hypothesis One 
 Hypothesis one stated that participants with higher physical functioning scores would 
have increased strength. This hypothesis was partially accepted. Increased strength was 
measured for flexion, extension, abduction and adduction with higher physical function. In all 
the aforementioned strength measures, a negative correlation existed where participants with 
increased strength had lower DASH scores. 
5.1.2 Hypothesis Two 
 Hypothesis two stated that participants with higher physical functioning scores would 
have increased range of motion. This hypothesis was partially accepted. This was only the case 
for internal rotation. Although the group with higher physical function scores generally had 
increased range of motion, they were not consistently statistically different. However, all other 
range of motion measurements had moderate to strong effect sizes (0.42-0.94). Negative 
correlations existed between DASH scores and internal rotation, flexion and abduction where 
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increased range of motion in these movements correlated with decreased DASH scores 
(increased physical function).  
5.1.3 Hypothesis Three 
 Hypothesis four stated that participants with higher physical functioning scores are more 
physically active than those with lower physical functioning scores. This hypothesis was 
partially accepted. Statistically, the two groups were not different when comparing the mean of 
physical activity in the groups with high and low physical function scores. However, a moderate 
correlation existed between DASH scores and physical activity, where participants with lower 
DASH scores (higher physical function scores) were more physically active.  
5.1.4 Hypothesis Four 
 Hypothesis six stated that there is no difference between baseline and follow up 
collections. This hypothesis was partially rejected. All strength measures were unchanged 
between baseline and follow-up. Only extension range of motion changed. Specifically, 
extension increased by 112% from baseline to follow-up. 
5.2 Quality of Life 
 For the purposes of this thesis, quality of life was defined with respect to physical 
function. All questionnaires used in this thesis had a score for physical functioning. The 
questionnaire chosen to represent physical function was the DASH questionnaire. In the current 
study, average DASH scores were 5 for the group with higher physical functioning and 30.67 for 
the group with lower physical function. 
 Quality of life can include representation of individuals function and abilities, with 
several factors affecting these measures. Surgical methods have showed a relationship to 
physical function quality of life scores in past studies. Patients who underwent breast conserving 
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therapy had higher ratings in physical function, social function and work and leisure activities, 
whereas those who underwent mastectomies reported lower scores for almost all physical 
function scales (Arndt et al., 2008). Mastectomies are more radical and damages more tissues 
than that of breast conserving therapy (Dalberg et al., 2010; Nesvold et al., 2008). With this more 
extensive damage, more side effects become present (such as lymphedema). Due to these 
complications overall well-being, as well as physical function decrease. With the decrease in 
function, patients may be unable to return to work, or if they do return, they have to change jobs 
or miss work. Ratings were also increased when employment was regained and fewer days of 
work were missed after diagnosis (Howard-Anderson et al., 2012). Overall, the interaction of 
treatment and quality of life is complicated and several other factors also contribute to function 
following treatment. DASH scores (as a representation for physical functioning) were correlated 
with strength (abduction, adduction, flexion and extension) and range of motion (abduction, 
flexion, internal rotation) measures in the current study. Overall function has had a demonstrated 
greater impact on quality of life than other factors (i.e. body image) (Kuehn et al., 2000; Rietman 
et al., 2003; Yang et al., 2010). Regaining function (strength and range of motion) plays an 
integral role in returning to regular roles. Literature has defined impairment as little as 10° loss 
of range of motion, and that a minimum of 120° of abduction is necessary to complete daily 
tasks (Badley et al., 1984; Kuehn et al., 2000). This suggests that survivors with DASH scores 
above 10 (where the current study was split), have some level of impairment. Following 
treatment, these decreases in strength and range of motion begin to impair everyday tasks. The 





The demographics of the breast cancer survivor population can influence the effects of 
treatment and function. Specifically, differing treatments, stage and the limb affected can change 
the rehabilitation outcomes and capabilities of the survivors afterwards. The breast cancer 
survivors involved in this study varied in these characteristics; radiation (n=4), chemotherapy 
(n=1), both chemotherapy and radiation (n=5), dominant limb affected (n=6), stage 1 (n=5), 
stage 2 (n=3) and stage 3 (n=2). The groups split by DASH scores however, were similar in 
stage, side affected, surgical intervention, age, height, weight and time since treatment. Although 
the groups were relatively small, these mitigating factors were evenly split between both groups. 
Therefore, the possible effects of each of these cannot be explored with respect to the current 
study. The groups in the current study differed in adjuvant therapy received. The group with 
higher self-reported physical function received a combination of both chemotherapy and 
radiation for adjuvant therapy (n=4) and, those with lower self-reported physical function scores 
often received only radiation therapy (n=4) (Table 6). Each group had one individual who 
differed on adjuvant therapy. The adjuvant therapies affect the body variously. Radiation therapy 
is localized and damages local cells surrounding the breast tissue, as well as causes scar tissue 
between the musculature at the glenohumeral joint leading to adhesions that may affect range of 
motion (Courneya et al., 2002; Hack et al., 1999; Lauridsen et al., 2008; Markes et al., 2006). On 
the other hand, chemotherapy manages cancerous cells that may not be detectable, and affects 
the cells in the whole body (Courneya et al., 2002). Hence, chemotherapy recipients often report 
decreased arm function, and are less likely to participate in exercise compared to those who do 
not receive chemotherapy (Markes et al., 2006; Tiezzi et al., 2016).  A combination of these 
treatments may result in symptoms from both. In the current study, the group that received only 
54 
 
radiation had lower physical function scores. This may be because these participants only had 
one area of their body treated, and were more aware of the deficits in this area. However, the full 
effects of treatments on physical function have not been fully explored. Treatment is complicated 
and it can be difficult to isolate which is influencing function. Surgery and adjuvant therapy 
interact differently for all patients, and it is important to continue to characterize these and 
interpret their relationship with function.  
Body fat percentage may also play a large role in function of breast cancer survivors. In 
the current study body fat percentage had a large effect size (Table 7). High physical functioning 
survivors had approximately 8% lower body fat, compared to the low physical function 
individuals. Individuals with higher percent body fat (and lower lean muscle mass) have 
decreased range of motion and strength (Park et al., 2010; Zoico et al., 2004). It is possible that 
due to the increased body fat these individuals already had reduced strength and range of motion, 
prior to treatment. Lower functioning individuals may have had less strength and range of 
motion prior, which further decrease with treatment. Future work to compare lean mass of the 
arm may provide insight as to whether a decrease in strength compared to muscle mass has 
occurred, and provide context into these lower strengths.  
5.4 Strength 
 The effect of strength on quality of life (as determined by DASH scores) was explored 
through comparison of two groups and correlation. When separating participants into groups of 
high and low physical function scores strength was 32 to 52% higher, in the group with high 
physical function scores compared to the group with low physical function scores for all strength 
measures except internal or external rotation. Additionally, the strongest correlation occurred 
with flexion strength (r=-0.50), than adduction (r=-0.48), followed by abduction (r=-0.45), and 
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finally extension (r=-0.41). Internal and external rotation strength were not correlated with 
DASH scores.  
 Correlations have been used in recent analyses to determine relationships between 
shoulder girdle strength and disability of the arm. Both the Pennsylvania shoulder score (PSS) 
and DASH score had moderate – strong correlation values for abduction, adduction and flexion 
(r-values ranging from -0.48 to -0.64) with the strongest Pearson correlation coefficient in 
adduction (Harrington et al., 2013), similar to the current findings. Two major functions of the 
pectoralis major are flexion and horizontal adduction. It is likely that the combination of 
treatments damaged the pectoralis major, causing greater functional disability, and thus 
decreased strength. In the current study these two exertions displayed significant group strength 
differences as for both group with low physical function scores (increased disability and 
decreased QOL) had lower strength. Harrington et al. (2011), reported that breast cancer 
survivors had 20-31% less strength in all shoulder girdle strength measures compared to healthy 
aged matched controls (Harrington et al., 2011). The participants in the group with high physical 
function scores in the current study had similar abduction strength values (16.5Nm) to the 
healthy aged matched controls (~20Nm), whereas the participants with low physical function 
scores had similar abduction strength (12.3Nm) compared to the breast cancer survivor group 
(~10Nm) (Harrington et al., 2011). The two groups in Harrington et al (2011) had significant 
differences in DASH scores, with the healthy aged matched controls having lower DASH scores, 
and PSS scores. These two findings suggest that those with decreased strength perceive daily 
tasks as more difficult and present with more disability.   
 Bilateral strength differences have limited documentation, but indicate a decrease in the 
affected limb, or no change. In the current study there were no significant differences in strength 
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between the limbs (~5%). Our findings are similar to a previous study, which found differences 
of 4-7% in extensors, protractors and retractors, with no difference in flexion strength (Merchant 
et al., 2008). Although different strength measures were investigated, the magnitude of change 
was similar between the two studies. Two implications arise: first, 23 participants were included 
in the study completed by Merchant et al (2008). In the current study, 10 participants were 
included for analysis, with a similar percent difference. With decreased power, these small 
changes were not significant (effect size 0.002-0.08). With both studies finding small changes in 
strength, it is likely that the effect of treatment is not isolated to just the tissue surrounding the 
breast.  
Breast cancer survivors may have generally lower strength compared to the population. 
Strength of a 50th percentile female adult was calculated as 25.6-44.6Nm using 3DSSPP software 
(3DSSPP, University of Michigan, Ann Arbor, MI). When compared to a 50th percentile adult 
female, participants in the current study had lower strength in all fundamental shoulder motions 
(Figures 7-12). It has been shown however, there is a loss of skeletal muscle mass due to aging 
(Janssen et al., 2002) leading to a decrease in strength (Hughes et al., 1999), which is not 
accounted for in the strength prediction. In addition to aging, these lower strengths are likely 
caused by the effects of various treatments. Compared to healthy women, patients who receive 
chemotherapy had 25% lower strength in lower extremities and 12–16% in upper extremities 
(Klassen et al., 2017). As stated above, there were no differences in strength between affected 
and unaffected limbs in the current study. As strength is decreased in the entire body, it is 
plausible that it affects both limbs similarly. Further, differences in strength may also be affected 
by hand dominance. Grip strength is altered between 10-30% due to hand dominance (Incel et 
al., 2002). Although grip strength is a combination of strength from the hand, wrist, forearm, 
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elbow, upper arm and shoulder, these differences exist in the muscles of the entire limb. With 
these considered, the modest differences between limbs in the current study can be a 
combination of dominance, and chemotherapy treatment side effects. Future work to compare to 
healthy age-matched controls will help contextualize these results and provide insight on whether 
the survivor population has generally lower baseline strength, accounting for the effects of aging. 
5.5 Range of Motion 
 The current study identified several correlations between DASH scores and specific 
shoulder ranges of motion. Three of the six motions had moderate negative correlations: internal 
rotation (r = 0.60), flexion (r = -0.45) and abduction (r = -0.30). When divided into groups, the 
group with higher physical function scores had 192% more internal rotation (~25°) than the 
group with low physical function scores. However, although not significant the group with high 
physical function scores had 12-88% more range of motion than the group with low physical 
function scores across the other five movements (effect sizes 0.48-0.94).  
 Range of motion recovery differs between survivors, and therefore the effects on quality 
of life can vary. The current study measured 8-25° (between groups) and 0-13° difference 
between limbs (on average) in support of previous literature. Reductions in range of motion of 
the affected limb in 1-67% of survivors  have been identified (Lee et al., 2008). Impairment is 
defined as a reduction in range of motion of 10° or more (Kuehn et al., 2000).  In extension, 
flexion, and internal/external rotation 90% of normal range of motion was recovered within 1 
year of surgery. However, in abduction 75% of survivors recovered only 60-80% of normal 
range of motion (Garusi et al., 2016). These differences in range of motion may be modest, but 
combined with additional symptoms can have lasting effects and decrease productivity. 
Approximately ¾ of women who returned to work presented with additional symptoms reducing 
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their capacity to perform at the workplace (Quinlan et al., 2009). As previously stated, quality of 
life ratings were increased when employment returned to normal (Howard-Anderson et al., 
2012). The combination of decreased range of motion, therapy effects, and strength differences, 
may have a large influence that results in lower physical function.  
The correlation between physical function scores and range of motion occurs for several 
movements. Spinelli et al (2016) used PSS scores and glenohumeral range of motion to correlate 
shoulder pain and disability with function. Glenohumeral external rotation during weighted and 
unweighted reaching were moderately correlated (r = 0.53-0.57) with the PSS-function sub-scale 
(Spinelli et al., 2016). Interestingly, pure external rotation was uncorrelated with DASH scores in 
the current study. Although changes may not be apparent in the comparison of range of motion, 
it is possible that compensatory strategies might be taken by those individuals who self-reported 
lower function to avoid painful motions.  
 Range of motion differences vary across the population and can have effects on daily 
tasks.  No differences existed between affected and unaffected limbs in range of motion in the 
current study. Participants differed between 0 and 40° across the movements collected. However, 
on average range of motion differed by ~5° between affected and unaffected limbs, representing 
0-55% difference in range of motion. However, several studies have reported restrictions in 
range of motion in this population. Previous research found restrictions of 10-21° in abduction 
(Kuehn et al., 2000; Reitman et al., 2004) and 5-12° in forward flexion (Kuehn et al., 2000; 
Reitman et al., 2004) between affected and unaffected limbs. When comparing pre and post-
surgery, flexion and abduction impairments are similar, with affected limb presenting with 5 and 
16° reduction in range of motion, respectively (Rietman et al., 2006). However, no glenohumeral 
motion differences occurred between women with breast cancer (affected arm) and healthy 
59 
 
controls during several activities (Spinelli et al., 2016). These, however were only comparing a 
few functional tasks (i.e. reaching with/without weight and combing hair). In the current study, 
more discomfort was reported in the affected limb during flexion and abduction range of motion 
tasks (0.5-2 out of 10) compared to the unaffected limb (0/10). Among other functions, pectoralis 
major is an agonist in glenohumeral flexion, and an antagonist in abduction. The surgical damage 
that was sustained by muscle, radiation and/or overall damage from chemotherapy produces scar 
tissue and adhesions (Lauridsen et al., 2008; Markes et al., 2006). It is possible that this damage 
is not extensive enough to limit range of motion, but could make these movements painful.   
Treatment type can influence range of motion. Patients with breast conserving therapy 
reported reductions in range of motion between 33 and 39% of the time. Increases in reduction in 
range of motion occurring following mastectomies, or radiation treatment may occur up to 77% 
of the time (Ebaugh et al., 2011; Harrington et al., 2013; Lauridsen et al., 2008; Nesvold et al., 
2008; Sugden et al., 1998; Thompson et al., 1995). Although minimal differences were found 
between the affected and unaffected limb in the current study, the patients with more extensive 
treatment were associated with less reduced range of motion capability.  The group with self-
reported high physical function scores received a combination of radiation and chemotherapy (4 
of 5 participants) and had 12-192% (effect sizes 0.48-1.89) more range of motion than the group 
with low physical function scores receiving just radiation therapy (4 of 5 participants). These 
treatments increase scar tissues and adhesions. It is possible that the self-reported restrictions 
indicated by patients relate to scar tissue and adhesions present after they receive treatment.  
5.6 Limitations 
 The work reported in this thesis should be considered within the scope of the various 
limitations. First, a limited number of participants participated in this study. With the strict 
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inclusion criteria and special population, recruitment was challenging. Figure 1 demonstrates the 
successful recruitment strategies as well as the number of participants excluded. The small 
sample size leads to a lack of power in analysis that was further depleted when groups were 
separated. However, this allows us to explore this population and the many characteristics that 
may differ between individuals. Second, in the strength and range of motion trials only one trial 
was taken for each task. Although this is not ideal for repetition, various protocols were adopted 
to ensure these trials accurately represented participant’s maximums, and to avoid fatigue and 
pain for future trials. Pilot participants indicated increased fatigue following strength trials, as 
well as total protocol taking too long (i.e. ~5 hours in length). With a special population, the 
protocol was reduced to mitigate the fatigue and length of the session. Additionally, physical 
function, as well as physical activity were both determined through the use of questionnaires. 
Both require self-reporting from participants and are therefore subjective measures. However, 
these measures represent a portion of participants’ lives that can be difficult to interpret with 
objective measures and allow us to explore the differences they experience outside of the 
laboratory setting. Range of motion tasks followed strength trials for all collections, and 
therefore the possibility exists that order effects were present within the range of motion tasks 
following maximal strength trials. Finally, strength can be contextualized with respect to body 
composition. Although not analyzed in this thesis, taking into account lean muscle mass may 
mitigate any impacts dominance may have had on strength measures. 
5.7 Future Work 
 Future work will aim to continue to quantify the abilities of breast cancer survivors. First, 
glenohumeral and scapular kinematics, as well as muscular activity, during various activities of 
daily living will be analyzed. This will provide more direct insight into the function of these 
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individuals, as well as possible adaptions to complete these tasks. Additionally, with additional 
data, further analysis of the effects of usual care (in a 4 month period) can take place. Finally, as 
a part of a larger scope, 2 more groups of individuals will be collected. First, another group of 
breast cancer survivors will participate in a 4-month exercise program. Healthy aged-matched 
controls will be the final group. This will allow for a more comprehensive evaluation of breast 
cancer survivor function (range of motion, strength, muscular activity and scapular kinematics). 
Comparisons can be made between survivors’ strength and range of motion to healthy age-
matched controls. Finally, an evaluation of a 4-month exercise program on function can be 
completed.  
5.9 Contributions 
 This thesis explores the differences in breast cancer survivors. First, this work will add to 
the limited literature on the acute breast cancer survivor population. Various characteristics were 
explored, with focus on strength and range of motion. Limited differences were found in the 
current study between affected and unaffected limbs, indicating an overall decrease in function in 
breast cancer survivors. Additionally, previous evidence indicated that survivors with lower self-
reported physical function scores have lower strength and range of motion. However, differences 
between groups with high and low physical function scores were previously undocumented. The 
current work quantified the differences between these two groups. In previous literature, 
strength, range of motion and muscular activity have been reported for all survivors as a whole. 
These variables have been inconclusive throughout literature. By separating survivors into two 
separate groups, the deficit experienced by some may be more accurately quantified and 
interpretation of specific deficits can be clarified. Furthermore, these variables have not been 
evaluated in a group of acute breast cancer survivors. By targeting the period following treatment 
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we are able to better evaluate strength and range of motion with minimal mitigation from other 




 This thesis evaluated strength and range of motion in a breast cancer survivor population. 
Comparisons were made between affected and unaffected limb as well as between participants 
with high and low physical function scores. Additionally, several participants were evaluated 
before and after a period of usual care. The following conclusions result: 
1. Participants with higher physical functioning scores exhibit increased strength in flexion, 
extension, abduction and adduction. 
2. Flexion, extension, abduction and adduction strength in the affected limb show moderate 
correlation with physical function (DASH) scores. 
3. No differences exist between affected and unaffected limbs in strength or range of 
motion.  
4. Participants with higher physical functioning scores exhibit increased internal rotation 
range of motion. 
5. Internal rotation, flexion and abduction range of motion in the affected limb show 
moderate correlation with physical function (DASH) scores. 
6. Physical functioning scores were moderately associated with physical activity: those who 
were more active had higher physical functioning scores.  
Acute breast cancer survivors have had minimal exploration. It is important to consider 
the immediate effects of treatment to strength and range of motion. With minimal differences 
between affected and unaffected limb in the current study, but overall less strength compared 
to the 50th percentile female strength abilities, function of both limbs should be considered. 
Several factors, such as physical activity and body fat percentage had large effect sizes and 
indicate that with a higher sample size, the influence of these variables on function can be 
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more thoroughly explored. Finally, this thesis has shown that there are differences in high 
and low functioning breast cancer survivors. These differences indicate that treatment affects 
individuals differently and these groups should be separated to better document the deficits in 
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Appendix A: Supplementary Materials 
Attached are the documents and questionnaires used in the collection of this thesis.  
Information Consent Form 
Title of Project: Longitudinal evaluation of upper limb functional capacity and body 
composition in breast cancer survivors 
Investigators:  
Marina Mourtzakis and Clark Dickerson, PhD  
Department of Kinesiology, University of Waterloo 
(519) 888-4567 Exts. 38549 and 37844 
 
Student-Investigator:  
Jackie Maciukiewicz MSc Candidate, Department of Kinesiology 
Research Assistant: 
Alicia Nadon, MSc., Department of Kinesiology 
Purposes of this Study: 
While 5-year breast cancer survivorship is 88% in Canada, up to 72% of breast cancer survivors 
(BCS) have upper limb impairments that remain following treatment. This can severely diminish 
quality of life, reducing the ability to complete activities of daily living (ADL) and successfully 
return to work. It is currently unknown which ADL tasks and arm postures pose the biggest 
problem for BCS, as prior studies have focused on coarse clinical measures. A refined definition 
of these deficits will provide critical information to aid in the development of targeted 
survivorship programs. In this project, we will assess functional impairment by measuring body 
composition, quality of life, and shoulder strength, range of motion, joint movement and 
muscular demands during ADL. This is one of the first studies that objectively looks at and 
quantitates shoulder function in breast cancer survivors. Understanding upper limb impairment in 
BCS will allow development of more specific and effective strategies to improve short- and 
long-term outcomes for BCS. These evidence-based strategies will be incorporated into existing 
75 
 
survivorship guidelines for breast cancer patients and clinical decision makers. The purpose of 
this study is: 
 to describe the upper limb impairment of breast cancer survivors in terms of body 
composition, kinematics, muscle activation and strength, and to relate these physical 
measures with objective and subjective measures of function and quality of life during 
ADL and work 
 finger prick to determine HbA1c (glycated haemoglobin) will allow for investigation 
into changes in average blood sugar levels over a period of 3 months. 
Who Can Participate:  
Participants in this study should be at least 3 months but less than two years post-treatment. They 
may have had Stage I to IIIa cancer, received any form of radiation therapy or chemotherapy, 
have undergone any form of surgical procedure for breast cancer removal, and have had any 
form of breast cancer pathology. Participants cannot have had bilateral cancer, metastases, 
barium swallow within previous 3 weeks of participation, women who are or suspect they are 
pregnant, or have had upper arm dysfunction prior to cancer treatments. Please note, only the 
female gender are being recruited for this study, as breast cancer is very rare among men (~1% 
prevalence) and the potential impairments we are describing have different characteristics across 
genders.  
Procedures Involved in this Study: 
The total in-lab time commitment for the participant will amount to approximately 4 hours; two 
2 hour collections are required, with a 16 week duration between each.   
Participant Information and Body Composition 
 Medical History: cancer type, treatment (surgery, chemotherapy, radiation and hormonal 
therapy), chronic conditions, medications, and any musculoskeletal injury that may limit 
performance 
 Anthropometric Measures (10 minutes): Measurements of standing height, weight and waist 
circumference will be taken. 
 FACT-B quality-of-life survey (10 minutes): This survey asks you to respond to questions 
using a rating scale for such things as your physical well-being (e.g., I have a lack of energy, I 
have nausea, I have pain).   You may, at any time, choose not to answer some or all of the 
questions by leaving them blank.   
 RAND 36-Item Health Survey Questionnaire (10 minutes) : This survey asks you to respond 
to questions using a rating scale for such things as your physical well-being and your physical 
functioning (e.g., During the past 4 weeks, have you had any of the following problems with 
your work or other regular daily activities as a result of your physical health?) 
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 DASH Questionnaire (10 minutes): This questionnaire asks you to respond to questions about 
symptoms related to your arm, shoulder, and hand as well as your ability to perform certain 
activities in the past week. (e.g. During the past week, were you limited in your work or other 
regular daily activities as a result of your arm, shoulder, or hand problem?) 
 DXA- Dual-Energy X-Ray Absorptiometry (20 minutes):  The DXA will be used to precisely 
measure lean tissue mass as well as body fat for the whole body and for specific regions of 
the body. There is a very low dose of radiation emitted, which is 200 times less than the limit 
for exposure to the general public (i.e. the radiation emitted from the scanner is 0.012 
mSV/DXA scan, where the maximal trivial dose is 5mSV/year for the general public. This is 
a very low dose of radiation emitted which is 200 times less than the limit for trivial exposure 
(and less than the amount of radiation you would be exposed to on a transatlantic flight).  This 
test requires that you put on a hospital gown, remove all jewellery and lie on an X-ray bed.  A 
certified Medical X-Ray Technologist (MRT) will conduct the scan. If you have had barium 
swallow in the past 3 weeks, you will not be eligible for the DXA scan.  You will be asked if 
you are taking oral contraceptives and if you are pregnant or if you suspect that you are 
pregnant.  The potential risks associated with radiation exposure to an unborn fetus are 
unknown. Thus, if you are pregnant, you will not be eligible for this assessment or study. 
 Bioelectrical Impedance Analysis (BIA) (5 minutes): To measure your body composition, you 
will be asked to void your bladder before the assessment. Two disposable adhesive electrodes 
will be placed on your foot (one above the middle toe and one on the ankle) and 2 on your 
hand (one on the middle finger and one on the wrist).  The skin will be cleaned with rubbing 
alcohol before placing the disposable electrodes. If you are allergic to rubbing alcohol, please 
indicate this to the researcher and the skin will be cleaned with water instead. The 4 electrodes 
will be connected to the cables where the signal is sent and received. If you have a pacemaker; 
this test will not be performed.  Otherwise, there are no risks involved in this assessment. 
 HbA1c Finger Prick (3 minutes): To measure your average blood glucose levels over the 
previous few months, we will do a finger prick analysis for glycolated haemoglobin using the 
HbA1c test. A trained phlebotomist (wearing disposable nitrile/vinyl gloves) will perform the 
test, in which you will provide one finger to prick. The finger will be wiped with rubbing 
alcohol, and pricked with a small device containing a lancet. If you are uncomfortable the 
procedure and/or allergic to alcohol wipes, you do not have to participate. In some cases, 
bruising or discomfort can result from the finger prick.   
Physical Activity and Rehabilitation Frequency Assessment 
 Godin Leisure Time Activity Questionnaire (5 minutes): In addition to each lab collection, 
you will receive (via preferred method – email or phone) this questionnaire once per month, 
which asks you to describe your level of physical activity in the 7 days prior. Four additional 
questions will evaluate the frequency of your rehabilitation visits. 
Biomechanical Shoulder Assessment 
 Biomechanical Shoulder Assessment (120 minutes): In order to systematically evaluate your 
shoulder function to describe upper limb capacities and dysfunctions in breast cancer 
survivors, we will perform a biomechanical assessment of your upper arm. This assessment 
includes arm motion, muscle coordination, and strength during activities of daily life and work 
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activities. The preparation and testing protocol that will be done in the laboratory is outlined 
below. 
Participant Preparation 
 It is recommended that participants are dressed in comfortable athletic or workout attire. A 
sleeveless shirt is required for the biomechanical shoulder assessment. Participants should avoid 
wearing clothing that has any metal or reflective pieces on it.  
EMG Preparation: EMG preparation will be performed by a female graduate student with 3 
years of experience with surface EMG. She has had both apprenticeship training from her 
supervisor as well as formal course training in a UW graduate program.  
 Prior to electrode placement, any hair in the placement area is shaved. The removal of hair 
enhances the signal and makes the removal of the electrode easier. A new disposable razor is 
used for each participant. Over 1000 participants have undergone this procedure in the 
Kinesiology department, and to date no participants have been cut. All shaving and electrode 
placements will be done by females. The skin areas for electrode placement are wiped with 
isopropyl alcohol and then the electrodes are placed on the skin. 
 Eight surface adhesive bipolar electrodes will be placed on the skin over 8 muscles on each 
arm (therefore 16 muscles total).  One additional electrode will be placed on the sternum as a 
ground electrode. On occasion the electrodes can leave a mark after removal. Usually, these 
marks disappear within hours or within two days. Should the irritation/redness last longer than 3 
days, please contact your physician. 
 You will then be asked to perform 14 maximal exertions that require full muscular effort for 
a total of five seconds each. Two rounds of each of these maximal voluntary muscle exertions 
will be performed for each muscle group. There will be 2 minutes rest in between each MVC in 
order to prevent fatigue. You will then be asked to lie down on a bench while remaining as 
relaxed and still as possible. This resting EMG trial will be used to remove bias in the signal. 
 On completion of the session the electrodes are removed and the skin is rubbed with 
isopropyl alcohol to remove any residual gel or adhesive material left behind from the electrodes. 
Motion capture preparation : Three-dimensional kinematics will be recorded using an 8-camera 
(2 MP) optoelectronic Vicon MX20+ motion tracking system (sampling rate 50 Hz) (Vicon, 
Oxford, UK). Thirty-nine reflective markers will be placed on the skin (adhesive backing) over 
the upper limbs, scapulae, thorax, head, and pelvis. The cameras will track these reflective 
markers, and these will be used to calculate joint angle. Some participants may experience mild 
skin irritation/redness from the tape used to attach the instrumentation to the skin. This is similar 
to the irritation that may be caused by a bandage and typically fades within 1-3 days. Should the 









Strength Trials: We will then measure isometric joint moment positions of the shoulder. 
Maximal voluntary force will be assessed at the hand using a 6 degree of freedom force 
transducer (FS6-500, AMTI); three 5 second trials will be performed for a total of 24 per 
participant. You will be pushing against a force transducer that will record how hard you push 
with your arm in four different positions. We will repeat the trials for both arms. At least two 
minutes rest will be given between trials to avoid fatigue. 
Shoulder Range of Motion (ROM): You will then be asked to move through a selection of active 
shoulder ROM positions. Movement (abduction, flexion, extension, and rotation of the shoulder) 
in each anatomical plane will be recorded using motion capture cameras.   
 
Performance of Activities of Daily Living: You will then be asked to perform a series of activity 
of daily living (ADL) tasks (12 in total). Examples of these are bra fasten, pour water from 
pitcher, push/pull, and forward reach. You will perform each task twice with both arms, however 
some require both hands and will only need two trials. You will be given at least two minutes 
rest between trials to avoid fatigue. A total of 40 trials will be collected.  
 
Rating of Perceived Exertion: Following the completion of each ADL task, you will be asked to 
rate your perceived exertion (RPE) on a calibrated, modified continuous Borg CR-10 scale for 
the neck, as well as each shoulder, elbow, wrist, and hand. At any point during the study, 
participants should advise the researcher if any of the movements or activities are causing 
discomfort or pain.  
 
Incidental Findings 
DXA: In addition to providing us with a measure of fat mass and lean mass, the DXA scan also 
estimates whole body and regional bone mineral content. The procedure for the DXA scan that we 
perform is not meant to accurately assess bone mineral density, however, the bone mineral density 
results that we collect from the DXA scan may provide a crude indication of potential measures of 
bone mineral density (i.e. whether one may have lower bone mineral density than for someone 
their age). It is your decision if you would like to be notified if we find that your bone mineral 
density if below what is considered normal. After receiving notification of your bone mineral 
density, we encourage you to share this information with your physician to discuss whether you 
should undergo a bone scan to more accurately measure your bone mineral density. 
Do you wish to be notified if we find your bone mineral density to be below what is considered 
normal? 
 I do wish to be notified if my bone mineral density is below what is considered normal. 
 I do not wish to be notified if my bone mineral density is below what is considered normal. 
Confidentiality and Security of Your Information and Data: 
To ensure the confidentiality of your data, you will be identified by a participant identification 
code known only to members of the research team. Your information will be stored in a locked 
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office at the Lyle Hallman building (0603) and Burt Matthews Hall (1404 and 1044) at the 
University of Waterloo. The information will be stored for a minimum of 25 years. Data will also 
be encrypted and stored on a password-protected computer and server.  
The data may need to be inspected from time to time for quality assurance (to make sure the 
information being used in the study is accurate) and for data analysis (to do statistical analysis that 
will not identify you).  The following organizations may do this inspection: the University of 
Waterloo Research Ethics Committee and other members of the research team (including monitors 
or auditors) as required, ensuring the safety of participants and the quality of data. 
Photographs and video recordings will be taken during the study, if you give consent to do so. 
These photographs or video recordings will be focused on the upper body and arm, but will not 
be focused on facial features. These photos and recordings are useful to verify the movement 
information recorded by the researchers, and may be helpful in teaching purposes such as when 
presenting the study results in a scientific presentation or publication. Any facial features or 
other distinguishing features that are visible in photos or recordings used for these above 
mentioned purposes will be blotted out to remove distinguishing features and maintain your 
confidentiality. 
Questions and Ethics Clearance: 
If you have any further questions or want any other information about this study, please feel free 
to contact:  
Marina Mourtzakis, PhD, Department of Kinesiology 888-4567 Ext.38459 
Clark Dickerson, PhD, Department of Kinesiology 888-4567 Ext. 37844 
This project has been reviewed by, and received ethics clearance through, a University of 
Waterloo Research Ethics Committee (ORE # 21124). If you have any questions, you may 
contact the Chief Ethics Officer, Office of Research Ethics, at 519-888-4567 ext. 36005 or ore-
ceo@uwaterloo.ca.   
Remuneration: 
You will be provided with a $50 gift card in appreciation for their participation in this study. The 
amount received is taxable. It is your responsibility to report this amount for income tax purposes.  
Changing Your Mind about Participation 
Participation is voluntary. You may withdraw from the study at any time without penalty. To do 
so, indicate this to a member of the team by saying, “I no longer wish to participate”. You may 
choose to have your data destroyed, or with your permission, your data will be used for the study. 
Please note, if you choose to withdraw at any time during the first session or before the start of the 
second session, you will receive a $25 gift card as part of remuneration.  
Consent to Participate 
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By signing this consent form, you are not waiving your legal rights or releasing the investigators 
(Professor Marina Mourtzakis and Professor Clark Dickerson) or involved institution (University 
of Waterloo) from their legal and professional responsibilities. 
 I agree to take part in a research study being conducted by Professor Marina Mourtzakis and 
Professor Clark Dickerson of the Department of Kinesiology, University of Waterloo. 
 
 I consent to the finger prick (HbA1c) test  
 
I have made this decision based on the information I have read in the Information letter. All the 
procedures, any risks and benefits have been explained to me. I have had the opportunity to ask 
any questions and to receive any additional details I wanted about the study.  
If I have questions later about the study, I can ask one of the researchers (Professor Marina 
Mourtzakis, 519-888-4567 Ext. 38549; Professor Dickerson, 519-888-4567 Ext. 37844). I 
understand that I may withdraw from the study at any time without penalty by telling the 
researcher.This project has been reviewed by, and received ethics clearance through, a 
University of Waterloo Research Ethics Committee (ORE # 21124). If you have any questions, 
you may contact the Chief Ethics Officer, Office of Research Ethics, at 519-888-4567 ext. 36005 
or ore-ceo@uwaterloo.ca.   
_____________________________    __________________________    
 Printed Name of Participant   Signature of Participant 
_____________________________   ___________________________ 
 Dated at Waterloo, Ontario    Witnessed 
Consent to Use Video and/or Photographs 
Sometimes a certain photograph and/or part of a video recording clearly shows a particular 
feature or detail that would be helpful in teaching or when presenting the study results in a 
scientific presentation or publication. If you grant permission for photographs or video recording 
in which you appear to be used in this manner, please complete the following section. Please 
note that any facial features will be blotted out so that you will not be identifiable.I agree to 
allow video and/or photographs to be used in teaching or scientific presentations, or published in 
scientific journals or professional publications of this work without identifying me by name. I 
understand that I retain the right to withdraw my consent to be video recorded or photographed at 
any time, and that existing video or photos may be destroyed at my request. There will be no 
penalty to me if I choose to refuse this consent. 
__________________________ _______________________________  
Printed Name of Participant   Signature of Participant 
 
_________________________ _______________________________  
      Dated at Waterloo, Ontario    Witnessed 
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Participant Information Form 
Participant ID:               
DIAGNOSIS INFORMATION 
Date of Diagnosis: ______________________________________________________ 
Type of Breast Cancer: __________________________________________________ 
Stage of Breast Cancer: __________________________________________________ 
 
TREATMENT INFORMATION      
            
Radiation Therapy: 
a. Start date: _________________________________      
b. Frequency (i.e. everyday, every other day etc):  _____________________________ 
c. Duration of therapy: _____________________  
d. Date of last radiation dose: _______________        
 
Surgery:  
a. Date of surgery(ies):____________________   
b. Type of surgery (lumpectomy vs mastectomy vs other): _____________________  
c. Side (R, L or both): ___________________________  
 
Chemotherapy: 
a. Start date:       
b. Total cycles:     
d. Date of treatments (e.g. Every Wednesday for 6 weeks): 
______________________________________________________________________________
__________________________________________________________________ 
e. Chemotherapy Drugs (if known):         
            ______ 
f. Did you have a PICC or port-a-cath? ______________________________________________ 
g. If yes, when was it removed? ___________________________________________________ 
h. Did you experience any pain or discomfort with it? 
______________________________________________________________________________ 
 




PHYSICAL ACTIVITY  
Are you currently physically active? (meet Canada’s P.A. Guidelines)     Yes   No 
Current Physical Activity 
i.e. lifting weights, cardiovascular activity, recreational or other unstructured physical activities 
that are part of  daily life/job?  
   
   
Previous Physical Activity 
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Physiotherapy and Exercise Prescription 
Have you ever been to a physiotherapy or other allied health professional for treatment regarding 
your arm or shoulder? ___________________________________________ 
 
If yes, how long did you receive treatment? __________________________________ 
What did the treatment involve? __________________________________________ 
 
Have you ever received an exercise program specifically for your arm or shoulder? _____ 
If yes, how long did you do the program for? ___________________________________ 
Are you still currently doing the program? _____________________________________ 
 
Do you have any difficulty in completing daily tasks? Yes / No 
a. If yes, what tasks di you have trouble doing (e.g., reach overhead, lifting)?: 
______________________________________________________________________________ 
Do you often feel tightness in the chest or shoulder of your affected arm? Yes / No 
If yes: 
Does this occur at a certain time of day or after a certain activity (i.e., morning, night, after 
exercise)? 
_______________________________________________________________ 
Does anything help ease the tightness (i.e., certain exercises, medications)? 
_______________________________________________________________ 
Do you experience the following in the chest/shoulder/arm of affected side? 
1. Pain________ 
2. Swelling________ 




7. Other? Please describe. 
 













CHECKLIST FOR SIGNS AND SYMPTOMS OF DISEASE 
 
Condition Yes No Comments 
Cardiovascular 
Hypertension    
Hypercholesterolemia    
Heart Condition    
Fainting/dizziness    
Chest pain    
Pulmonary 
Asthma    
Bronchitis    
Emphysema    
METABOLIC 
Diabetes    
Excess weight changes    
Thyroid disease    
MUSCULOSKELETAL 
Osteoporosis    
Arthritis     
Low back pain    
Swollen joints    
Orthopedic pain    
Artificial joints    
 
OTHER 
    
    
    
    
    
 
PRESENT MEDICATIONS (name, dose, frequency: i.e. Aspirin/325 mg/ 1 daily)  
Name Dose Frequency Comments 
    
    
    
    
    





Supplement 3 – Amendment 
Godin Leisure-Time Exercise Questionnaire 
1. During the past 7 days (week), how many times on the average do you do the following kinds of 
exercise for more than 15 minutes during your free time (write appropriate number on each line).  
 
                                                                                              Times per Week                                          
a) STRENUOUS EXERCISE                                                ____________                                
 (HEART BEATS  RAPIDLY)  
 (e.g., running, jogging, hockey, football, soccer, squash, basketball, cross country skiing, judo, roller 
skating, vigorous swimming, vigorous long distance bicycling)  
b) MODERATE EXERCISE                                                  ____________                                        
       (NOT EXHAUSTING)                         
 (e.g., fast walking, baseball, tennis, easy bicycling, volleyball, badminton, easy swimming, alpine skiing, 
popular and folk dancing) 
 c)  MILD EXERCISE                                                              ____________                                    
(MINIMAL EFFORT)  
(e.g., yoga, archery, fishing from river bank, bowling, horseshoes, golf, snowmobiling, easy walking) 
2. During the past 7 days (week), in your leisure time, how often do you engage in any regular activity 
long enough to work up a sweat (heart beats rapidly)?  Please check one. 
 
 1.  Often _______          2. Sometimes  ______  3. Rarely/Never _______ 
 
Rehabilitation Assessment 
1. Do you have an additional health practitioner or rehabilitation specialist (chiropractor, physical 
therapist, naturopath, other)? 
 
 




3. Do you continue to do exercises prescribed by a specialist in your own home? 
 
 





The Rand SF 36 Quality of Daily Living Questionnaire  
 
PT#                Session#       Date     
The following questionnaire asks questions to gain insight into a picture of your daily health. 
For each question, please circle one number that most appropriately describes your 
situation. Please let us know if you have any questions throughout.  
 
1. In general, would you say your health is : 
Excellent            1 
Very Good          2 
Good                 3 
Fair                   4 
Poor                  5 
2. Compared to one year ago, how would you rate your health in general, now: 
Much better now than one year ago   1 
Somewhat better now than one year ago  2 
About the same      3 
Somewhat worse than one year ago   4 
Much worse now than one year ago   5 
The following items are about activities you might do during a typical day. Does your 




Yes, Limited a 
Little 
No, Not limited 
at All 
3. Vigorous activities, such as running, lifting 
heavy objects, participating in strenuous sports 
[1] [2] [3] 
4. Moderate activities, such as moving a 
table, pushing a vacuum cleaner, bowling, or 
playing golf 
[1] [2] [3] 
5. Lifting or carrying groceries [1] [2] [3] 
6. Climbing several flights of stairs [1] [2] [3] 
7. Climbing one flight of stairs [1] [2] [3] 
8. Bending, kneeling, or stooping [1] [2] [3] 
9. Walking more than a mile [1] [2] [3] 
10. Walking several blocks [1] [2] [3] 
11. Walking one block [1] [2] [3] 
12. Bathing or dressing yourself [1] [2] [3] 
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During the past 4 weeks, have you had any of the following problems with your work or 
other regular daily activities as a result of your physical health? 
 
Yes No 
13. Cut down the amount of time you spent on work or other activities 1 2 
14. Accomplished less than you would like 1 2 
15. Were limited in the kind of work or other activities 1 2 
16. Had difficulty performing the work or other activities (for example, it 
took extra effort) 
1 2 
During the past 4 weeks, have you had any of the following problems with your work or 
other regular daily activities as a result of any emotional problems (such as feeling 
depressed or anxious)? 
 
Yes No 
17. Cut down the amount of time you spent on work or other activities 1 2 
18. Accomplished less than you would like 1 2 
19. Didn't do work or other activities as carefully as usual 1 2 
20. During the past 4 weeks, to what extent has your physical health or emotional 
problems interfered with your normal social activities with family, friends, neighbors, or 
groups?  
Not at all    1 
Slightly    2 
Moderately    3 
Quite a bit    4 
Extremely    5 
21. How much bodily pain have you had during the past 4 weeks? 
None     1 
Very mild     2 
Mild     3 
Moderate     4 
Severe             5 




22. During the past 4 weeks, how much did pain interfere with your normal work 
(including both work outside the home and housework)?  
Not at all    1 
A little bit     2 
Moderately     3 
Quite a bit    4 
Extremely    5 
These questions are about how you feel and how things have been with you during the 
past 4 weeks. For each question, please give the one answer that comes closest to the 
way you have been feeling.  





















23. Did you feel full of 
pep? 
1 2 3 4 5 6 
24. Have you been a 
very nervous person? 
1 2 3 4 5 6 
25. Have you felt so 
down in the dumps that 
nothing could cheer you 
up? 
1 2 3 4 5 6 
26. Have you felt calm 
and peaceful? 
1 2 3 4 5 6 
27. Did you have a lot of 
energy? 
1 2 3 4 5 6 
28. Have you felt 
downhearted and blue? 
1 2 3 4 5 6 
29. Did you feel worn 
out? 
1 2 3 4 5 6 
30. Have you been a 
happy person? 
1 2 3 4 5 6 
31. Did you feel tired? 1 2 3 4 5 6 
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32. During the past 4 weeks, how much of the time has your physical health or 
emotional problems interfered with your social activities (like visiting with friends, 
relatives, etc.)? 
All of the time             1 
Most of the time    2 
Some of the time    3 
A little of the time             4 
None of the time    5 












33. I seem to get sick a 
little easier than other 
people 
1 2 3 4 5 
34. I am as healthy as 
anybody I know 
1 2 3 4 5 
35. I expect my health to 
get worse 
1 2 3 4 5 
36. My health is excellent 1 2 3 4 5 
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